Practice Guidelines: For Family Physicians

Practice Guidelines
For Family Physicians

Volume 4
Volume 4
V
o
l
u
m
e

4
i
Message from His Excellency

Prof. Dr. Hatem El Gabaly
Comprehensive development and modernization is one of Egypts priorities and
pursued objectives. Out of this rule, we are committed towards improving the
quality of health care services available for all Egyptians; adults, children, the poor
and the well-off.
The Ministry of Health and Population has adopted, as a top priority, developing
current systems to provide and nance health services in guidance and vision of the
political leadership to ensure high quality in service provision and meet needs and
expectations of the population as well as keeping up with top-notch developments
at all levels: Primary, Secondary and Tertiary.
This vision has been translated into a promising and ambitious Five Years Plan to
institutionalize the Health Sector Reform Program on the national level. The plan
is focusing on implementing the Family Health Model at all primary health care
facilities in the 27 Governorates.
Our dream has been realized into a competent program of Health Sector Reform
aiming to provide every person with high quality health services. These include
physical, psychological and social welfare, which translate into high production
and progress for our cherished Country, Egypt.
I am delighted to introduce to one of the important publications for the Sector of
Technical Support and Projects, representing a great team effort The Practice
Guidelines for Family Physicians for the family physician at all Family Health
Units of MOHP Distributed all over the Country.

Prof. Dr. Hatem El Gabaly
Minister of Health and Population
Volume 4
ii
V
o
l
u
m
e

4
Preface
The Ministry of Health and population is working diligently to achieve equal and
available quality health services for all citizens of Egypt. Our objective is to shape
national policies for the goal of advancing health care delivery in all parts of the
country.
Six years ago, the Ministry has adopted new policies and strategies in order to
provide basic health services of high quality for all citizens in the framework of the
Family Health Model. This has led to introducing new nancing mechanisms that
ensure the sustainability of nance and resources, and availability of affordable
services along with effectiveness and efciency of these services.
Having made situational analysis in details, highlighting points of weaknesses and
strengths and dening actual needs, strategic plans were subsequently developed
putting into practice the reforming infrastructure and human resources as well as
partnerships between governmental, private and national sectors.
It gives me great pleasure to present this document. This system is in continuous
reform, progressing incrementally, rening the knowledge base, and modifying
concepts. This document is not the end product, but rather the rst step of many
others.
However, I hope it will help us towards our ultimate goal of a quality, effective,
efcient, evidence based service to all Egyptians irrespective of geographical or
social and economic barriers.
The document is a collaborative work of the Ministry of Health and Population staff,
and the Sector for Technical Support and Projects on both central and peripheral
levels. Work in this document is subjected to continuous assessment, operation
research, many of the issues presented in this document will be updated in further
version.
Dr. Emam Mossa
Undersecretary of the Sector for
Technical Support and Projects
Volume 4
V
o
l
u
m
e

4
iii
Volume 4
iv
V
o
l
u
m
e

4
Volume 4
V
o
l
u
m
e

4
v
Volume 4
vi
V
o
l
u
m
e

4
List of Figures
No Title Page
1 Flow Chart Diagram For Differential Diagnosis of Hemoptysis 12
2 Flow Chart Diagram For Differential Diagnosis of Cough 12
3 Flow Chart Diagram For Differential Diagnosis of Weight Loss 13
4 Flow Chart Diagram For Services Delivery of Tuberculosis 14
5 Flow Chart Diagram For Standardized Management Plan for TB Suspects (WHO) 17
6 Flow Chart Diagram For Differential Diagnosis of Nausea and Vomiting 58
7 Flow Chart Diagram For Differential Diagnosis of Dysphagia 60
8 Flow Chart Diagram For Differential Diagnosis of Heamatemesis 61
9 Flow Chart Diagram For Differential Diagnosis of Melena 62
10 Flow Chart Diagram For Differential Diagnosis of Hiccups 63
11 Flow Chart Diagram For Differential Diagnosis of Acute Diarrhea 64
12 Flow Chart Diagram For Differential Diagnosis of Chronic Diarrhea 65
13 Flow Chart Diagram For Differential Diagnosis of Steatorrhea 67
14 Flow Chart Diagram For Differential Diagnosis of Constipation 68
15 Flow Chart Diagram For Differential Diagnosis of Fresh Rectal Bleeding 69
16 Flow Chart Diagram For Differential Diagnosis of Acute Abdominal Pain 70
17 Flow Chart Diagram For Differential Diagnosis of Abdominal Pain Chronic &Recurrent 72
18 Flow Chart Diagram For Differential Diagnosis of Ascites 73
19 Flow Chart Diagram For Differential Diagnosis of Abdominal Swelling Focal (Upper) 74
20 Flow Chart Diagram For Differential Diagnosis of Hepatomegaly 74
21 Flow Chart Diagram For Differential Diagnosis of Splenomegaly 76
22 Flow Chart Diagram For Differential Diagnosis of Flank Mass 76
List of Tables
No Title Page
1 Standard code for TB treatment Regimens 18
2 TB Treatment Outcome 19
3 TB Adverse Reactions and their Management 20
4 Score System for TB 22
5 Stepwise Approach for Managing Asthma In Adults and Children Older than 5 Years of Age 41
6 Continued: Stepwise Approach for Managing Asthma In Adults and Children Older than 5 Years of Age 43
7 Usual Dosage for Long-Term- Control medications in "Asthma" 44
8 Continued:Usual Dosage for Long-Term- Control medications in" Asthma" 45
9 Continued: Usual Dosage for Quick-Relief Medication in" Asthma" 47
Volume 4
V
o
l
u
m
e

4
vii
Abbreviations and Acronyms
BACTEC : Detection of Metabolic End Products of TB Bacilli
BCG : TB vaccine
DOTS : Directly Observed Treatment With Short Course Chemotherapy
E : Ethambutol
H : Isoniazide
MDR : Multiple Drug Resistance
NGOs : Non Governmental Organizations
NTP : National Tuberculosis Program
PAL : Practical Approach to Lung Health
PCR : Polymerase Chain Reaction
PHC : Primary Health Center
R : Rifampcin
S : Streptomycin
TB : Tuberculosis
Z : Pyrazinamide
1
Communicable
Diseases
DOTS/ Treatment
of
Tuberculosis
V
o
l
u
m
e

4
11
Communicable Diseases
1. DOTS/ Treatment of Tuberculosis
DOTS Treatment of (T.B)
Tuberculosis
Def inition
Transmission
Role of The F.H.U and Center
National Tuberculosis Control Program Services
Delivery Chart
Diagnosis
Case Def inition
Standardized Management Plan For TB Suspect
Standard Code for TB Treatment Regimens
Treatment Regimens in Special Situations:
Pregnancy
Breast feeding
Oral contraception
Hepatic insufciency
Acute hepatitis
Diabetes mellitus
Renal failure
HIV infection
Monitoring of treatment of T.B
Treatment outcome
Adverse reaction and their management
Adherence to treatment
Recording
Reporting
Multi-drug resistant cases
T.B in children
Factors determining the epidemiology
Investigations
Score system
Treatment
Preventive chemotherapy
Health education
Preventive measures:
General
Specic
PAL
Tuberculosis
Def inition
It is an infectious disease caused by Mycobacterium
Tuberculosis or Mycobacterium Bovis.
Transmission:
Inhalation: most common
Ingestion: contaminated milk
Cutaneous: no epidemiological study
Mother to Fetus: transplacentaly aspirating
amniotic uid
When to Suspect TB:
Persistent cough > 2 weeks
Blood stained sputum
Breathlessness and chest pain
General symptoms:
`loss appetite & loss weight
Malaise &tiredness
Night sweat & night fever
History of contact with TB patient
Sharp angular deformity of the spine
Chronic diarrhea
DOTS/ Treatment of Tuberculosis
12
V
o
l
u
m
e

4
Cough
Sputum
Little or No Sputum
Purulent
Non-purulent
With fever
No fever
Pneumonia
Abscess
Tuberculosis
Chronic Bronchitis
Bronchiectasis
Foreign Body
Ca of Lung
Tuberculosis
Emphysema, Chronic
Pulmonary Fibrosis
Early Pulmonary
Embolism
Early Congestive Heart
Failure
Mediastinal Tumours
Asthma
Viral upper respiratory
infection
Lung tumour
Reux esophagitis with
aspiration, Smoking,
Toxic Fumes, Hay Fever
& Asthma
Primary atypical
pneumonia silicosis
Bloody
Mucoid Foamy
See haemoptysis
Asthma
Congestive Lf
Heart Failure
No Dyspnoea Dyspnoea
Hemoptysis
No chest pain
Chest pain
No fever
Fever, purulent
sputum
Pulmonary
Embolism
No Dyspnoea
Cardiomegaly or
Murmur
Dyspnoea
Cardiomegaly or
murmur
Pneumonia
Lung abscess
Tuberculosis
Bronchiectasis
Carcinoma of lung
Bronchiectasis
Tuberculosis
Parasitic infection
Fungal infection
bronchial adenoma
Congestive Lf
Heart Failure,
Mitral Stenosis
Refer cases if persistent > 2 weeks
Haemoptysis: Coughing of blood
Refer for further evaluation
Figure 1: Flow Chart Diagram For Differential Diagnosis of Hemoptysis
Figure 2: Flow Chart Diagram For Differential Diagnosis of Cough
V
o
l
u
m
e

4
13
Weight Loss
Normal or increased appetite
Anorexia
Thyroid
Not enlarged
Enlarged Thyroid
Diabetes mellitus
Iatrogenic
Hyperthyroidism,
Bulimia
Hyperthyroidism
Normal physical
exam
Normal Chest
X-Ray
Abnormal chest x-ray
Anorexia nervosa
Simmonds disease
Drugs, Scurvy
Malabsorption syndrome
Uremia
Carcinoma of
lung, tuberculosis,
congestive heart
failure
Hyperpigmentation
Lymphadenopathy
Abdominal Mass
Addisons Disease Leukemia
Sarcoidosis
Lymphoma
Splenomegaly Midepigastrum Hepatomegaly
Renal mass
Leukemia
lymphosarcoma,
Hodgkins disease
Collagen disease
Carcinoma
of stomach,
intestine or
pancreas, colon
Liver cirrhosis
Liver carcinoma
metastatic cancer
Hypernephroma
Wilms tumor
Hydronephrosis
Polycystic kidney
No fever
Fever
Tuberculosis
Other febrile
illnesses
AIDS
Collagen disease
Lymphoma
Abnormal physical exam
Figure 3: Flow Chart Diagram For Differential Diagnosis of Weight Loss
14
V
o
l
u
m
e

4
Role of the F.H.U. and Centre:
Provide TB patients with daily supervised
treatment with anti-TB drugs according to
prescribed regimen, dosage and duration.
Provide patients, who are unable to attend
at the PHC centre on a daily basis (e.g.,
handicapped patients) with supervised
treatment at the patients home.
DOT at the patients home, if necessary.
Retrieve patients who did not attend the PHC
centre for their daily treatment.
Record daily attendance and anti-TB drug
intake in the TB treatment card.
Health education and counselling to TB
patients, their contacts and the community.
Timely referral of TB patients to the chest
clinic for follow up sputum examination.
Order and collect the required quantity of
anti-TB drugs for TB patients.
Ensure that the anti-TB drugs present in the
unit are not expired.
Prepare monthly reports to chest clinic on:
o No. of TB patients treated at PHC
centre;
o Amount of drugs administered;
o Balance of drugs
Refer contacts of TB patients to chest clinic.
Refer TB suspects to chest clinic.
National Tuberculosis Control Programme Service Delivery Chart
Department for curative services Department for preventive services
DG for Chest Diseases
NTP manager
Chest Disease
Facility
Chest Disease
Facility
Chest Disease
Facility
FHU FHU FHU
FHU
FHU
FHU
FHU FHU FHU
Diagnosis
Diagnosis of Tuberculosis
Routine sputum collection:
Day 1 sample 1 - Patient provides, under supervision, an on-
the-spot sample when he presents to the health facility
Patient gets a sputum container to take home for an early-
morning sample the following morning
Day 2 Sample 2 - Patient brings an early morning sample
Sample 3 - Patient provides another on the spot
sample under
supervision
NB: If a patient is unable to produce a sputum
sample, a nurse may help him to give a good
cough and bring up some sputum. This must be
done in a well-ventilated area, preferably in the
open air.
Value and Role of Diagnostic
Tools for Pulmonary TB
A) Bacteriology:
1. Detection of TB bacilli
Figure 4: Flow Chart Diagram For Services Delivery of Tuberculosis
National
level
Governorate
level
District
level
V
o
l
u
m
e

4
15
Direct smear microscopy stained by the Zeil-
Neelsen
Cultures: it takes 4-8 weeks
Allows study of anti TB bacilli
2. Detection of immune response of TB bacilli:
Tuberculin Test:
0.1ml of tuberculin is injected intradermally,
induration is measured after 48 to 72 hours 10mm
= positive previously vaccinated. if not
vaccinated consider TB
infected person
Negative no TB infection or false
negative
False Negative
Host Factors
Acute or overwhelming tuberculosis.
HIV infection and other immune-suppressive
diseases (lymphoma, etc.)
Viral infections (e.g., Measles, Mumps,
Varicella)
Live virus vaccination (e.g., Measles)
Renal failure.
Malnutrition.
Sarcoidosis.
Factors Related to Testing Procedure
Improper storage of PPD
Improper dilution.
Subcutaneous injection.
Lack of experience in interpretation
3. Histo-pathological diagnosis of TB
4. BACTEC
5. PCR
NB: 3, 4 & 5 not in FHU
B) Radiography
No chest x-ray pattern is absolutely typical of
pulmonary TB
What is a Case of Tuberculosis?
A patient in whom TB has been bacteriologically
conrmed or diagnosed by a clinician.
The purpose of case def inition is:
Proper patient registration and case notication
Prioritized treatment of sputum smear-positive
cases, the main sources of infection in the
community
Allocation of cases to appropriate standardized
treatment regimens
Evaluation of the proportion of cases according to
site, bacteriology and treatment history
Cohort analysis of treatment outcomes
Why match standardized treatment regimen
to diagnostic category?
The reasons for matching standardized treatment
regimen to diagnostic category are:
To avoid under-treatment of previously treated
cases and therefore to prevent acquired resistance
To maximize cost-effective use of resources and
to minimize side-effects for patients by avoiding
unnecessary over-treatment
What determines case def inition?
The four determinants of case def inition are:
Site of TB disease.
Bacteriology (result of sputum smear).
Severity of TB disease.
History of previous treatment of TB.
Diagnostic Classification of Tuberculosis
A) Def initions of Pulmonary Tuberculosis
1. Smear-positive pulmonary TB
A sputum smear-positive pulmonary TB
patient is dened in one of three ways
A patient with at least two sputum
specimens positive for acid-fast bacilli
by microscopy
A patient with at least one sputum
specimen positive for acid-fast bacilli
by microscopy, and radiographic
abnormalities consistent with pulmonary
TB, and a decision by a physician
to treat with a full course of anti-TB
chemotherapy; or
A patient with at least one sputum
specimen positive for acid fast bacilli
by microscopy, which is culture positive
for M. tuberculosis
2- Smear-negative pulmonary TB
Two sets (taken at least 2 weeks apart) of
16
V
o
l
u
m
e

4
at least two sputum specimens negative
for acid-fast bacilli on microscopy and
radiographic abnormalities consistent
with pulmonary TB and a lack of clinical
response despite one week of a broad-
spectrum antibiotic and a decision by
a physician to treat with a full curative
course of anti-TB chemotherapy; or,
A patient who fulf ills all of the following
criteria:
o severely ill and at least two sputum
specimens negative for acid-fast
bacilli by microscopy and radiographic
abnormalities consistent with extensive
pulmonary TB (interstitial or military)
and a decision by a physician to treat
with a full curative course of anti-TB
chemotherapy; or, A patient whose
initial sputum smears were negative,
who had sputum sent for culture initially,
and whose subsequent sputum culture
result is positive; or,
o A patient whose initial sputum smears
were negative and is diagnosed positive
for acid-fast bacilli by other diagnostic
means.
B) Def inition of Extra-Pulmonary
Tuberculosis
A patient with clinical and/or radiological and
histological evidence consistent with active
extra-pulmonary tuberculosis and a decision
by a physician to treat with a full curative
course of anti-TB chemotherapy; or
A patient with at least one culture specimen
from an extra-pulmonary site positive for
Mycobacterium tuberculosis.
The Following Def initions Are Used:
New: A patient who has never had treatment
for TB or who has taken antituberculosis
drugs for less than 1 month.
Relapse: A patient previously treated for TB who
has been declared cured or treatment completed,
and is diagnosed with bacteriologically positive
(smear or culture) tuberculosis.
Treatment after failure: A patient who is
started on a re-treatment regimen after having
failed previous treatment.
Treatment after default: A patient who
returns to treatment, positive bacteriologicaly,
following interruption of treatment for 2
months or more.
Transfer in: A patient who has been
transferred from another TB register to
continue treatment.
Other: All cases that do not t the above
def initions. This group includes chronic
case, a patient who is sputum-positive at the
end of a re-treatment regimen.
Note
Smear-negative pulmonary and
extra-pulmonary cases may also
be relapses, failures, returns after
default or chronic cases. This should,
however, be a rare event, supported
by pathological or bacteriological
evidence (culture).
Case Finding
Case f inding policy
A) Passive Case Detection
Individuals who have symptoms and who seek
health care.
B) Active Case Detection
The health care providers go to the community
to detect TB cases;
1. Contacts of pulmonary TB patients.
2. Individuals who are in need of a health
certicate.
3. Other risk groups:
Health staff, especially laboratory staff
dealing with sputum examination.
Closed communities, e.g. army, prison, etc.
Patients with immuno-suppressive
diseases, e.g., diabetes, renal failure,
HIV infection.
Patients under immuno-suppressive
treatment, e.g., corticosteroids, anti-
cancer therapy.
V
o
l
u
m
e

4
17
TB Suspect
AFB Microscopy
AFB ---
AFB +--
AFB +++
++-
Broad spectrum
antibiotics
x-ray & physicians
judgement
Improved
(not TB)
No improvement
Repeat AFB microscopy
AFB ---
X-ray &
physicians
judgement
Consider other
diagnoses
Treat as
Smear negative
PTB
Treat as
Smear positive
PTB
AFB +++
++-
+--
Yes TB
Standardized Management Plan for TB Suspects (WHO)
Standard Code for TB Treatment
Regimens
The number before a phrase is the duration of that
phase in months.
A subscript number after a letter indicates the
number of doses of that drug per week.
If theres no subscript number, treatment is daily.
Yes TB No TB
Figure "5": Flow Chart Diagram For Standardized Management Plan for TB Suspects (WHO)
18
V
o
l
u
m
e

4
Table.1: Standard Code for TB Treatment Regimens
Tb Diagnostic
Category
Tb Patients
Tb Treatment Regimens
Initial Phase
Continuation
Phase
I
New smear-
positive
patients;
New smear-
negative PTB
with extensive
parenchymal
involvement;
or severe
forms of
EPTB
2 HRZE 4 HR
II
Previously
treated sputum
Smear-
positive PTB:
- relapse;
treatment after
interruption;
or treatment
failure
2 HRZES/1
HRZE
5 HRE
III
New smear-
negative PTB
(other than in
Category I);
or Less severs
forms of
EPTB
2 HRZE 4 HR
IV
Chronic and
MDR-TB
cases
(still sputum
- positive after
supervised re-
treatment)
Specially designed standardized
or individualized regimens are
suggested for this category
Direct observation of drug intake is required
during the initial phase of treatment in smear-
positive cases, and always in treatment that
includes Rifampicin.
Streptomycin may be used instead of
Ethambutol. In meningeal TB, Ethambutol
should be replaced by Streptomycin.
Whenever possible, drug sensitivity testing is
recommended before prescribing treatment
in failure cases.
Contacts of patients with culture-proven
MDR-TB should be considered for early
culture and sensitivity testing.
Treatment Regimens in Special Situations
There are a number of special conditions in which
different treatment options should be advised. The
most important of these conditions are mentioned
blow.
Pregnancy
A pregnant TB patient should not stop her
treatment since the growing foetus is more
endangered by untreated TB of the mother than
by a correctly prescribed treatment. However,
streptomycin should not be administered during
the f irst trimester of pregnancy, because of the
possible damage of the 8th cranial nerve. The
recommended regimen for pregnant TB patients
is: 2HRZ/ 7HR
Breastfeeding
A breast-feeding woman with TB should receive
a full course of anti-TB drugs. All anti-TB drugs
are compatible with breast-feeding and the woman
can safely continue of breast- feed her baby (See
also Tuberculosis in Children).
Oral Contraception
Rifampicin interacts with oral contraceptive
medications with a risk of decreased protective
efcacy against pregnancy. A woman receiving
oral contraception may choose between two
options while receiving treatment with ethambutol:
following consultation with a clinician, an oral
contraceptive pill containing a higher does of
estrogen (50g) may be taken, or another form of
contraception may be used.
Hepatic Insufficiency
Patients with liver enzymes that do not exceed
double the normal value should receive the
treatment regimen recommended for their case
def inition.
Rifampicin may need to be stopped if the liver
enzymes are raised after starting the treatment.
Patients whose liver enzymes reach more
than double their normal value after the start of
treatment or, whose liver enzymes are constantly
elevated after the start of treatment, should receive
a treatment regimen with 2SHE/10HE.
Under no circumstances should pyrazinamide
be given to patients with active liver disease.
Acute Hepatitis (E.g., Acute Viral
Hepatitis)
The Combination of Streptomycin and
Ethambutol is the safest option until the hepatitis
has resolved and can be given up to a maximum
duration of three months. The patient can then
receive a continuation phase with 6HR, as long
V
o
l
u
m
e

4
19
as liver enzymes and serum bilirubin are within
normal values and sputum smears are negative.
If not, a continuation phase with 10 HE is
recommended.
Diabetes Mellitus
In the presence of TB diabetes becomes more
difcult tomanage, as is thecasewithother chronic
infectious disease. Once TB treatment is started
the management of diabetes becomes easier.
Therefore, patients with diabetes and TB should
be given treatment regimens according to their
case def inition.
Renal Failure
Patients with renal insufciency should be
followed by renal function tests. Take into
consideration that isoniazid and pyrazinamide
have cumulative effects. Patients with renal
insufciency should not be given ethambutol and
streptomycin. For patients with impaired renal
function the recommended regimen is 2HRZ/
7HR.
HIV Infection
HIV Infection and TB (see also Chapter TB and
HIV)
HIV positive patients with TB should not be
given thiacetazone. Also streptomycin should,
preferably, not be included. The recommended
regimen is 2EHRZ/ 10 HE. Infection with atypical
Mycobacteria is common in HIV positive patients,
e.g., Mycobacterium Avium Complex, which will
not respond to the anti-TB drugs used.
Monitoring of Treatment
Monitor the sputum smear examination
results at regular intervals during treatment,
usually at the end of the second month (end
of third month for retreatment cases); end of
the fth month, and at the end of treatment
after six or eight months, depending on the
type of treatment.
In the areas implementing DOTS, monitor
the drug intake for patients who are on daily
supervised treatment during the intensive
phase, and on weekly supervised treatment
during the continuation phase.
Practical Issues When Monitoring
TB treatment:
In pulmonary smear-positive cases, the
conversion of sputum smears from smear-
positive to smear-negative is the best early
indicator that chemotherapy is taken regularly
and effectively.
After two months of chemotherapy more
than 80% of NEW pulmonary smear-positive
cases should have converted to smear-
negative, and after three months this rate
should increase to more than 90%.
To determine the CURE RATE (also
called success rate), add the number of new
pulmonary smear-positive cases cured to the
number of new smear-positive cases who
completed then divide the resulting numbers
by the total number of new pulmonary smear
positive cases. Multiply the number by 100 to
obtain the cure rate in percent.
One of the main objectives of NTP is to
cure more than 85% of new smear positive
pulmonary TB cases put on treatment.
Treatment Outcome:
Table.2: TB Treatment Outcome
Cure
A patient who is smear-
negative in the month of
treatment and on at least
one previous occasion
Treatment completed
A patient who has
completed treatment but
who does not meet the
criteria to be classied as a
cure of a failure
Treatment failure
A patient who remains
or becomes again smear-
positive at ve months or
later during treatment
*
Died
A patient who dies for any
reason during the course of
treatment
Default
A patient whose treatment
was interrupted for two
months or more
Transfer out
A patient who has been
transferred to another
reporting unit outside the
Governorate and for whom
the treatment outcome is
not known.
20
V
o
l
u
m
e

4
Adverse Reactions And Their
Management:
Table.3: TB Adverse Reactions and Their Management
Side Effect
Responsible
Drug (s)
Management
1- Minor Side
Effects
- Anorexia,
Nausea,
Abdominal pain
- Joint pains
- Burning
sensation in feet
- Orange/red
colour of urine
Rifampicin

Pyrazinamide
Isoniazid
Rifampicin
Always Continue
Treatment!
Take drugs at night
Acetyl salicylic acid
Pyridoxine 100mg daily
Reassurance
2- Major Side
Effects
Stop Responsible Drug!

- Itching of skin/
skin rash

Streptomycin
Stop streptomycin
- Hearing
impairment or
Deafness

Streptomycin
Replace Streptomycin
with Ethambutol
- Dizziness
(vertigo/
nystagmus)

Streptomycin
Replace Streptomycin
with Ethambutol
- Jaundice Most anti-
TB drugs
Stop all drugs; urgent
liver function tests and
prothrombin time
- Vomiting
and confusion
(suspect acute
liver failure)
Most anti-
TB drugs
Stop all drugs; urgent
liver function tests and
prothrombin time
- Visual
impairment
Ethambutol Stop Ethambutol
Shock; purpura;
acute renal failure
Rifampicin Stop Rifampicin
Adherence To Treatment:
At least two health workers from each PHC
unit must be trained on how to implement
DOTS. If possible, some volunteers (NGOs)
should attend this training session.
Preventive Measures To Minimize Treatment
Interruption
At the time of registration of a TB patient starting
treatment, sufcient time should be set aside
Record the patients address and other relevant
addresses
Identify potential problems
Inform the patient about the duration of treatment
need consult ahead of time in case of permanent or
temporary change of address.
Corrective Measures to Minimize The
Duration of Treatment Interruption:
Enquiries and nd out the cause of the patients
absence. The patient should be contacted the next
day after missing treatment during the initial phase
and within a week during the continuation phase.
Recording
A) Tuberculosis Treatment Card (TB/01)
This card is kept at the chest facility where the
patient is registered. It provides information about
the patient, as we ll as on disease classication,
sputum examination, defaulter action and treatment
outcome. The card also contains information
on administration of drugs during the initial
intensive phase supervised by the health worker
and administration of drugs during continuation
phase.
B) Tuberculosis Identity Card (TB/02)
This card has to be kept by the patient. It
contains information on the patient; the disease
classication; the date of start of treatment; and the
treatment regimen. The card also shows the date of
the next appointment.
C) Chest Clinic Tuberculosis Register
(RB/03)
The Tuberculosis register is an essential tool
for programme monitoring. The register is kept at
the chest facility and contains information on all
TB patients registered in that facility. The register
consists of two pages: the f irst page contains
all elements of identication of the patient, the
diagnosis, and the treatment prescribed; the
second page contains information concerning
case management, evaluation of bacteriological
examination, and the outcome of treatment. Most
of the columns are self-explanatory.
D) Laboratory Register (TB/04)
This register is kept at laboratories of all chest
facilities performing sputum smear examinations
for AFB. For diagnostic purposes a total of three
sputum specimen must be examined and recorded,
and two for each follow-up of patients. All results
of diagnostic examinations must be entered.
E) Request Form for Sputum Examination
(TB/05)
It is important to indicate in this form whether
the sputum is sent for diagnosis, for follow-up or
V
o
l
u
m
e

4
21
for a health certicate. In the former case a detailed
address should be given for the patient, so that the
patient can be traced in case he does not return to
the health facility and the sputum is found to be
smear-positive.
F) Tuberculosis Culture/Sensitivity Test
Request Form (TB/06)
Request for culture/sensitivity test will be sent
from the chest facility to the Central on Intermediate
Laboratories (when designated) in case of failure
to respond to short course chemotherapy, or before
commencement of re-treatment regimens.
G) Tuberculosis Referral / Transfer Form
(TB/07)
This form will be used when transferring patients
from one chest facility to another. It will be f illed in
triplicate: the f irst copy will be given to the patient
(to hand over at the next chest facility); the second
is sent to the chest facility directly; and the third
copy is kept for records. The receiving chest facility
will f ill the bottom half of the form and return it to
the referring or transferring facility, as soon as the
patient presents himself at the facility. The private
practitioner who wants to refer his patient to the
district chest facility can also use this form.
Reporting
A) Quarterly Report on Case Detection
(TB/08)
This report contains information on new cases
(pulmonary smear-positive, pulmonary smear-
negative and extra-pulmonary cases) and smear-
positive cases put on retreatment regimen (relapse,
treatment after default and treatment failure). If
also reports on the activities of the laboratory.
B) Quarterly Report on The Treatment
Outcome (TB/09)
This report provides information about the
treatment outcome of all smear-positive cases:
new smear-positive cases: smear-positive relapses
and other re-treatment cases that were registered
in the chest facility 12 to 15 months earlier)
C) Quarterly Report on Sputum
Conversion (TB/10)
This report shows the results of sputum smear
examination after two and/or three months of
treatment of sputum smear-positive patients
registered 3-6 months earlier. This report provides
the chest facility staff, GCT and NTP management
with an early indicator of the effectiveness of
treatment.
Tuberculosis in Children
Factors determining the epidemiology of
tuberculosis in children:
Socio- economic factors:
Crowded houses, poor ventilation, and malnutrition
resulting from poverty and ignorance.
The transmission of tuberculosis infection:
The main source of infection is an adult with
smear positive sputum.
Consequences of developing active
pulmonary tuberculosis:
The younger the age the higher the mortality.
Those who survived the primary infection
either pulmonary or extra-pulmonary
appeared less susceptible to the adult-type of
pulmonary tuberculosis later on in their life
Clinical Findings:
Clinical ndings are frequently non specic.
The presence of phlyctinular conjunctivitis,
erythema nodosum, lymphadenopathy or
heptosplenomegaly must lead to consideration of
possible Tuberculosis.
Investigations:
Tuberculin Test
It is one of the cornerstones of the diagnosis. In
absence of BCG vaccination or after 3 years of
vaccination, an induration of > 10mm is indicative
of infection with M. tuberculosis. In a child,
within the f irst 3 years of vaccination with BCG,
an induration of > 15mm indicates infection with
M. tuberculosis. A false negative tuberculin test
may be seen in malnutrition, following whooping
cough or childhood viral infections, during
corticosteroid therapy, overwhelming bacterial
infections including tuberculosis.
Chest Radiography:
Ghons focus (alveolar Consolidation)
Mediastinal lymph glands enlargement
Complications of either or both: Cavities,
(Collapse) and Inltration
Miliary shadows
22
V
o
l
u
m
e

4
Sputum Examination:
Gastric aspirate of the early morning after 8-
20 hours fasting or laryngeal swabs. Hypertonic
saline induced sputum via nebulizer bronchial
alveolar lavage.
Routine Blood Picture
Blood picture is of little diagnostic value. ESR
is raised and mild anemia is accompanied by a
degree of monocytosis.
Special Investigations (Refer)
Biopsy of accessible tissues; bronchoscopy bone
marrow aspiration.
Score System
A score of 7 or more indicates a high likelihood
of TB
Table.4: Score System for TB
Feature 0 1 2 3 4 Score
General
Duration of
illness
2 w
<
2-4w 4 w >
Weight for
age
80%
>
60-80% 60% <
Family
history
-VE Reported
Proved
+VE
Tuberculin
test
Positive
Malnutrition
Not
improving
After 4 w
Unexplained
fever and
night sweats
No
response
to non-
specic
treatment
Local
Lymph
nodes
Joint
or bone
swelling
Angle
deformity
of the spine
Total score
Treatment of Childhood Tuberculosis
2 HRZ/ 4HR. Streptomycin can replace
Rifampicin or Pyrazinamide if any of them
is contra-indicated. Streptomycin should be
added in the following conditions:
Severe forms of TB, e.g., TB meningitis,
military TB
Re-treatment cases (relapse case,
Treatment failure cases and treatment after
interruption)
Immuno- suppressed patients.
Preventive Chemotherapy:
A6 month course of preventive treatment with
daily Isoniazid (5mg/kg) is effective. Close family
contacts of smear-positive sources.
Target groups for preventive treatment
Infants of Mothers with PTB
A breast-feeding infant has a high risk of
infection from a mother with PTB, and a high
risk of developing TB The infant should receive
6 months Isoniazid treatment, followed by BCG
immunization. An alternative policy is to give 3
months Isoniazid, then perform a tuberculin skin
test. If the skin test is negative, stop the Isoniazid
and give BCG. If the skin test is positive, continue
another 3 months Isoniazid, then stop Isoniazid
and give BCG.
V
o
l
u
m
e

4
23
Children Under 5 Years of Age
It is important to screen child house-hold
contacts of adults with sputum smear-positive
PTB. Screening identies those children less
than 5 years of age without symptoms. Give these
children 6 months Isoniazid preventive treatment.
Children under 5 years of age with symptoms need
investigation for TB. If investigations show TB, the
child receives anti-TB treatment. If investigations
do not show TB, the child should receive Isoniazid
preventive treatment.
HIV- Infected Individuals
Controlled clinical studies have shown that
Isoniazid preventive treatment reduces the risk
of TB disease in HIV- positive individuals also
infected with M. tuberculosis.
Preventive Measuses for
Tuberculosis
General Measures:
Environmental sanitation
Legislation (e.g., free contact examination)
Health education.
Good ventilation.
Good nutrition.
Pasteurization or sterilization of milk.
Specific Measures:
BCG Vaccination
Vaccinate all children at birth with BCG. To give
protection against the serious forms of TB such as
TB meningitis military TB which is commonest in
the under 5 years age group.
Maximum effect is in the f irst 3-5 years after
vaccination.
The Prevention of Tuberculosis in
Health Care Facilities:
Patient Education
Sputum Collection
Sputum collection always should be outside
(open environment) and away from other people,
not in small rooms such as toilets or other enclosed
areas.
Outpatient Settings
Patient waiting areas should be open and well-
ventilated. Patients who may have infectious TB
should be triaged to separate clinics or waiting
areas
Inpatient Management:
Separation and Isolation Policies
Establish separate wards or rooms for conrmed
infectious TB patients and the wards should be
well-ventilated.
Reducing Exposure in the
Laboratory
Sputum collection should not take place in
the laboratory area.
A pass-through window should be used to
deliver sputum samples.
Radiology
Radiology Departments Should Attempt to:
Provide coughing patients with a surgical
mask to wear; alternatively provide tissues
or cloth.
Provide expedited priority service to
potentially infectious TB patients to minimize
the length of time spent in the department.
Use the room with the best ventilation for
taking images of potentially infectious TB
patients.
Sputum Induction and Cough-
inducing Procedures
Cough-inducing procedures (e.g.,, sputum
induction or bronchoscopy) should be done only
when absolutely necessary on patients who may
have TB Likewise, bronchoscopy should be used
as a last resort after other less risky diagnostic
measures have been taken.
Practical Approach to Lung
Health (PAL)
Up to one third of patients over the age of
ve years attending FHU seek health care for
respiratory symptoms. Ideally, TB cases should
be detected among patients with respiratory
symptoms within FHU.
2
Treatment of
Helminthes
V
o
l
u
m
e

4
27
Treatment of Helminthes
Helminths
Nematodes:
Entrobius
Ascaris
Strongyloids
Ancylostoma
Trichuris trichura
Trematodes (Flukes):
Schistosomiasis
Fasciola
Cestodes (Tape Warms):
Tenia saginata
Tenia solium
Hymenolopis nana
Echinococcus (Hydatid)
Protozoa
1- Blood and tissue: Malaria
2- GIT: a) Amoebae
b) Giardia
1- Nematodes
Mebendazole is an effective anthelmintic and has
been used successfully in the treatment of pinworms,
whipworms, hookworms, and roundworms.
Entrobius:
100 mg (1 teaspoon / 1 tablet) once. Then
repeated after 2 wks for all ages
Other Nematodes (Ascaris-Ancylostoma -
Trichuris-Strongyloids):
100 mg twice / day for 3 days for all ages.
2- Trematode
Schistosomiaisis (Bilharziasis)
Fasciola
Both Praziquantel (tab. 40mg/kg), single dose.
Praziquantel: 600mg/ tablet, 60mg /ml
The dose of Praziquantel for Schistosoma
haematobium or mansoni, 40mg/kg/day orally
divided in 2 doses for 1 day is given; 75mg/kg/
day for 1 day is used for liver ukes (Clonorchis
sinensis/Opisthorchis viverrini).
Fasciola:
You can refer cases of Fasciola for Egantin
(human labendazole)
3-Cestodes
T.Saginata: Praziquantil 10mg/kg, single dose
T.Solium: Praziquantil 50mg/kg/d in divided
three doses for10 days
You can give Niclozamide ( yomezan ) 4
tablets chewing once for those > 6 yr & half
dose if < 6 yr. (not in EDL)
Hydatid: Refer.
H.nana:praziquantel 25mg/kg if heavy repeat
after 7 days
or you can give
- yomezan ; 4 tablets chewing in 1st day then 2
tablets chewing for the next 6 days.
- Half dose for those < 6 yr.
Children: plaziquantel 10-20mg/kg
Protozoa
`Blood & tissue:
Malaria treatment:
P.Vivex, ovale, malaria & CQ sensitive P.
aciparum:
Chloroquine 600mg
Then 300mg after 6 hours
Chloroquine tab 250 &200mg- syrup 80mg/ml
Prophylaxis:
No CQ resistance: Chloroquine 300mg
weekly
CQ resistance: Meoquine 250mg weekly
28
V
o
l
u
m
e

4
Mef loquine
Acute Disease
- Initial dose, 5 tablets (1250mg) given as a single
oral dose.
Prophylaxis - Usual dose, 250mg per week prior
to departure, during period in endemic area and 4
weeks after return
or
Doxycycline 100mg daily
Chloroquine tab 250&200mg - syrup 80mg/ml
GIT Protozoa:
E. Histolytica:
Adult 500-750 mg three times/day for ten
days.
Children 50 mg/kg divided on 3 equal doses/
d for 10 days.
Giardia:
Adult > 12 yr: 250 mg three times 1 day
for 1 wk.
Children < 12 yr: 25 mg/kg divided on 3 equal
doses/d for 1 wk.
3
Urinary Tract
Infections (UTI)
V
o
l
u
m
e

4
31
Urinary Tract Infections (UTI)
UTI is one of the most common conditions seen
in general medical practices.
Risk Factors
Diabetes Mellitus
Pregnancy
Menopause
Urinary stasis
Genitourinary malformation
Stones
Genitourinary instrumentation
Catheterization
Sexual intercourse
Delayed micturition
Dehydration
Treatment
Encourage uid intake
Antibiotics e.g. Trimethotrim, Ciprooxacin
Investigation
Urine analysis (midstream urine)
Culture & sensitivity of urine (send urine
sample before giving antibiotics)
Consider further investigation if:
o Recurrent urinary tract infection
o Suspect pyelonephritis
o Unclear diagnosis
o Unusual organism
Ask For:
1. Urea & cereatinine in blood
2. PSP (if man >40)
3. Plain X-ray & US & IVP
Refer
Refer to the Specialist:
If any abnormalities are detected
Or persistent symptoms in spite of therapy
Prescsibing in Renal Patients
Roles of the kidney in dealing with drugs
1. Drug elimination (clearance).
2. Proximal tubular secretion of drugs.
3. Activation of drugs (vit.D, Insulin).
4. Inactivation of drugs (Imipinem),B lactam..
5. Secretion of hormones (Erythropoeitin)
6. Target for hormonal action (PTH, Calcitonin,
ADH, Aldosterone).
7. Autacoid (Local Hormone) production (PGs,
Renin,Endothelins).
Drug Clearance By The Kidney
It is Controlled by the following factors:
A- Renal Blood Flow & Glomerular Filtration.
It is increased by:
Vasodilators, Digoxin, Other inotropics,
Methyl xanthines.
It is decreased by:
Vasoconstrictors, ACEI, AR blockers,
Beta- blockers, Verapamil&other negative
inotropics.
B-Changes of PH of The F ilterate:
Acidic drugs (e.g., Salicylates, Barbiturates,
Sulphonamides, etc..) are better eliminated
renally in alkaline urine.
Meanwhile, basic drugs (Atropine,
Amphetamine, Ephedrine, etc..) are better
eliminated in acidic urine.
N.B.
Urine is rendered Acidic by:
Ascorbic acid, Nalidixic acid, Ammonium
chloride, methenamine.
Alkalinization is produced by:
Sodium bicarbonate, Lactate, Citrate,etc..
C-Physico- Chemical Properties of Drugs
(Polarity,Size of the molecules, lipid solubility,
etc.)
It follows the same principles mentioned in the
chapter dealing with drug absorption.
D- Drug Secretion by Tubules:
Proximal Tubular Secretion of Drugs
Tubular secretion of drugs or body excreta
like Uric acid occurs in the proximal
convoluted tubules(S1&S2).
32
V
o
l
u
m
e

4
Examples of drugs eliminated by this route
include:
Acidic Agents (Anions):
Penicillins, Cephalosporins. Methotrexate
Thiazides, Loop Diuretics, Salicylates,
Indomethacin, Acetazolamides.
Basic Agents (Cations):
Quinine, Quinidine, Atropine, Morphine,
Pethidine, Adrenaline
TMP, Quat.Ammon.Comp. Amiloride,
Triametrine, Histamine.
Some drugs inhibit this tubular secretion of
others,leading to elevation of plasma level of
the latter; e.g.:
a. Probenicid inhibits tubular secretion
(T.S.) ofpenicillins, cephalosporins,
chloramphenicol, leading to rise of
their plasma level (Useful drug/drug
interaction).
b. Probenicid inhibits T.S.of thiazide and
loop diuretics, and thus inhibit their
diuretic effect, as they must act from the
luminal side of the tubules.
c. Quinidine inhibits T.S. of
digitalis,leading to rise of digitalis
plasma level and may contribute to
toxicity.
d. Chlorpropamide inhibit T.S. of
dicoumarol and warfarin which
may lead to bleeding tendency unless
the dose is adjusted.
Activation of Drugs in the Kidney
Vitamin D (25-OH-ase) 25-OH Cholecalciferol

(1-Alpha-OH ase) 1,25 (OH)2 Chole-Calciferol(CC)
{Active Vit.D} InKidney
In the liver
Thus in CRF,use one alpha preparation,
Not vitamin D,due to deciency of one alpha
hydroxylase enzyme in cases of CRF.
Inactivation&biotransformation of drugs
in the kidney
Imipinem(Beta lactam Antibiotic) is
inactivated by Renal Dihydro-peptidase
(DHP).
Cilastatin inhibits DHP,and protects
imipinem.Thus the combination Imipinem/
Cilastatin(TIENAM)in used as an effective
stable Beta lactam,in bacterial infections.
Small MW proteins and Polypeptides,e.g.,
Insulin, PTH, Calcitonin etc are partially
cleared by the kidney, Thus their clearance
is reduced in CRF& their T1/2 prolonged,
So Diabetic Needs for insulin is Reduced as
their Renal Function Declines.
Oxidation of Salicylates,acetaminophen in
renal tissues shares for pathogenesis of renal
toxicity of these drugs.
Endocrine function of the Kidney
Secretion of Erythropoeitin(EPO),to stimulate
Bone Marrow for RBCs production, Thus in
CRF,anemia is a sign,treated by EPO,which is
mandatory in these cases.
Target for Hormonal actions
1-PTH(Parathormone hormone):
Stimulates reabsorption of Calcium from
distal CT.
Inhibits Phosphate reabsorption from all
segments of the nephron..
Stimulates 1-Alpha- OH ase in the kidney.
2-Calcitonin:
Inhibits reabsorption of Calcium and
phosphate from all segments of the nephron.
3-ADH:
Increasing permeability to water in Distal
&Collecting Tubules.
Used in Treatment of Diabetes Insipidus(Pit.
type).
Overproduction of ADH (syndrome of
inappropriate ADH production SIADH)
hyponatremia, volume expansion,
natruresis.
It is due to many causes of which DRUGS;
e.g., Desmopressin, Oxytocin,Vincristine,
Chlorpropamide, Nicotine, Chlorophospha
mide,Morphine,Amitriptyline, SSRI.
V
o
l
u
m
e

4
33
This condition is treated by Lithium or
Demeclocycline Plus acute correction of
Hyponatremia with this formula:
4-Aldosterone:
Which control Sodium,Potassium exchange
in Distal CT.
Aldosterone Antagonists are used as
Potassium Sparing Diuretics,especially in
cases of Hyperaldosteronism(CHF, Liver
Cirrhosis,Nephrotic Syndrome, etc..), and
in combination with other hypokalemic
diuretics.
Renal Autacoids
1-Prostaglandins:
PGE
2
(Medullary), PGI
2
(Cortical), F
2
, D
2
,
TXA
2
.
They have the following Functions:
1. It counterbalnces the Renin Angiotensin
System (RAS) in control of hypertension
(HTN).
2. It controls RBF &GFR & CCM (Counter
Current Multiplier) system.
Note
NSAIDs (as cyclooxygenase
blockers) block synthesis of PG
synthesis leading to decreased
RBF & GFR. -Hyperkalemia-
TINs(Toxicity).
COX-II in the kidney has
constitutive functions,
Thus even selective COX-
II inhibitors (Celecoxib,
Rofecoxib, Nemisulide,
Meloxicam, Valdecoxib, Etc)
Have the same effects like other
NSAIDs.
3. Diuretic action of Loop Diuretics is mediated
partly by renal PGs.Thus: NSAIDs (Selective
and Non-selective COX-II inhibitors) antagonize
the diuretic effect of Loop diuretics.
2-RENIN:
Secreted by JGA (Juxtaglomerular Apparatus),
for control of glomerulotubular functions.
Its secretion is controlled by B-receptors,
Renal electrolytes, blood volume and HCT
(heamatocrite) value.
Angiotensinogen
(RENIN) Release of Hypoten.PGs
Angiotensin-I Bradykinin Inactive
(Angiotensin Converting Enzyme"ACE")
Angiotensin-II Ang.III.
Direct Vasoconstriction.
Stimulation of B-receptors.
Release of Catecholamines from their stores.
Release of Aldosterone.
Release of ADH.
Growth factor of Cardiac MFs&Vascular
SMFs.
Feedback inhibition of release of RENIN
Note
Effect of ACEI&Arblockers is
hazardous in Volume depleted rather
than normal persons.
3-Endothelins:
(ET
1
, ET
2
, ET
3
), acting on ET
A & B
receptors.
They ineunce epithelial cell proliferation &
Solute transport(ET
B
),induce VC (ET
A&B
)
Their level increases in acute&Chron.R.D.
Their antagonists are in early Clinical trials.
Changes in the Pharmacokinetics
&pharmacodynamics of drugs in
cases of impaired renal function
Absorption:
May be impaired due to nausea,vomiting of
uremia.
Some unabsorbable drugs are absorbed e.g.,
Aminoglycosides, Aluminium preparations
(Antacids or as phosphate binders).
Volume of Distribution:
May be increased or decreased, thus changing
the total dose required(Serum conc.X V
d
).
Protein Binding:
Some patients are Hypoproteinemic (e.g.,
Nephrotic syndrome), thus increasing free drug
34
V
o
l
u
m
e

4
level,and needing dose adjustment especially of
highly protein bound drugs.
Note
Excess H+ in such cases of
CRF occupy the receptor sites
for acidic drugs e.g. Sulpha,
Penicillins,Salicylates.Thus increasing
the free fraction of these drugs.
Metabolism&Biotransformation:
Reduced for drugs like Vit.D and Polypeptides
(Insulin).
End Organ Sensitivity:
May be changed, e.g. Thiazides have little diuretic
effect in severe RF,and they are contraindicated in these
cases,as they reduce renal blood ow.
Renal Clearance of drugs:
It is reduced due to accumulation of drugs or
their metabolites.
Remember
Uremia may be precipitated by drugs increasing
protein catabolism e.g., Corticosteroids and
tetracyclines (except doxycycline).
Do Not Forget
Points to keep in mind when prescribing
a drug for a renal patient
Is treatment by the drug mandatory?
Can the drug reach its site of action in
suitable concentration? (Nitrofurantoin is
not suitable in CRF)
Is drug kinetics altered in CRF?
Will the drug or its metabolite accumulate in
CRF?
Is the drug Nephrotoxic?
Will the drug worsen the uremic state?
(e.g., Tetracycline)
Is the drug Sodium or Potassium salt?
Adjust the dose guided by creatinine level or
creatinine clearance.
The dose should be titrated by Clinical
effects.
Early detection of Toxicity & Drug
Monitoring.
Remarks
Renal impairment,according to CrCl,is
divided into:
o Mild(20-50ml/min.)
o Moderate(10-20ml/min.)
o Severe if less than 10ml/min.
ACEI: Use with caution in renal impairment.
Avoid if CrCl is less than 30ml/min.
Allopurinol toxicity and rash is seen with
moderate impairment, if severe, dont exceed
100mg/day.
With severe impairment,Aluminium
absorption and accumulation is increased.Its
absorption is increased by Citrates present in
effervescent forms.
Max.dose of Benzyl Pen.with renal
impairment is 6g/day, Neurotoxicity and
convulsions are expected.
Beta Blockers in Renal impairment: Use
Small doses of Atenolol,Nadolol,Sotalol,Pin
dolol. Reduce Acebutolol dose. With severe
impairment, they reduce RBF leading to
more deterioration of the case.
Erythromycin max.dose in severe renal
impairment is 1.5g/day, Ototoxicity is
expected.
Higher doses of Frusemide and Bumetanide
are needed with moderate renal impairment.
Deafness may follow rapid IV Lasix.
4
Management
of Respiratory
Tract Diseases
& ENT
V
o
l
u
m
e

4
37
Management of Respiratory Tract
Diseases & ENT
Management of Respiratory
Tract Diseases & ENT
Sore Throat (Pharyngitis & Tonsillitis)
Its a common condition occurs, more in
children & young adults.
Pharyngitis
&tonsillitis
Viral
Most common
70% of cases
Bacterial
A B-hemolytic
streptococcus
Others
Atypical agents
Noninfectious
causes
Investigation:
Throat swabs cannot distinguish Commensal
Organisms from Clinical Infection, are
expensive & do not give instant results so
rarely used.
Rapid antigen tests give immediate results
but have low sensitivity (60%)
Management:
A. For viral pharyngitis, treatment is
symptomatic, analgesia & antipyretics,
increase uid intake & gargle with oral
antiseptic or salt water.
B. For possible streptococcal throat
begin antibiotics, aiming at preventing
complications such as rheumatic fever &
Glomerulonephritis.
Treatment of Choice:
Penicillin oral or Intramuscular:
A. Penicillin V 500mg 3/day or 4/day for 10
days
B. Benzathine penicillin 1.2 million units
IM (Do sensitivity test for penicillin)
(Be familiar with symptoms, signs &
treatment of anaphylaxis & observe
patient for 30 minutes after injection)
C. Erythromycin can be used if patient is
allergic to penicillin (250mg / 6 hr for 10
days)
Note
If rash appeared when using
Amoxicillin consider the case
as glandular fever (Infectious
mononucleosis) and refer to
specialist.
D. If history of rheumatic fever look at
Rheumatic fever chapter & IMCI.
Do Not Forget
Indication for referral for tonsillectomy
Recurrent acute tonsillitis more than 5
attacks causing school absence in a year.
Airway obstruction caused by very large
tonsils causing sleep apnea.
Chronic tonsillitis is staying more than 3
months causing halitosis.
Recurrent quinsy (Peritonsillar Abscess)
If there is unilateral Tonsillar enlargement
to exclude malignancy.
Health Education:
Teach parents & patients to go to hospital
immediately if the pain becomes severe or if
dyspnea, difculty in swallowing, excessive
salivation& inability to fully open the
mouth.
Patients with streptococcal pharyngitis
should not return to school or work until they
have stopped antibiotic therapy for a full 24
hours.
Hoarseness
Def inition:
Change in quality of the voice affecting pitch,
volume or resonance.
Occur when vocal cord function is affected by
change in the cords, neurological or muscular
problem.
Hoarseness
Local causes
- Upper respiratory
tract infection
- Laryngitis
- Trauma (shouting,
coughing, vomiting)
- Reux
- Instrumentation
Neurological
problem
- Laryngeal nerve
palsy
- Motor neuron
disease
- Myasthenia Gravis
- Multiple sclerosis
Muscular problems
- Muscular dystrophy
- Functional problems
- Hysterical paralysis
Clinically viral & bacterial infections are indistinguishable.
38
Diseases & ENT
V
o
l
u
m
e

4
Management:
Refer all cases with hoarseness lasting more
than 3 weeks for ENT assessment to exclude
carcinoma.
Refer cases to specialist according to history
& physical examination.
Treat cases of upper respiratory tract infection
& laryngitis. Rest voice, analgesia & steam
inhalations. Consider antibiotics if bacterial
infection suspected.
Stridor
Noise created on inspiration due to narrowing of
the larynx or trachea. Children are more affected
than adults.
Causes of Stridor
Congenital abnormalities of the larynx
Epiglottitis
Croup (Laryngotracheobronchitis)
Inhaled foreign body
Trauma
Laryngeal paralysis
Treatment:
I.V cortisone
Refer to ENT specialist.
Look at more details in Emergency Chapter.
Nasal Problems
Foreign Bodies in The Nose
Foreign bodies in the nose are common in young
children.
Refer all children with unilateral offensive
discharge to ENT specialist, for exploration under
general anesthesia.
Do not try to remove yourself unless the object
is very supercial &the child is co-operative. You
might push object further in causing trauma.
Injury to The Nose
Injury can be to the nasal skin (laceration),
bone (fracture) or cartilage (septal hematoma
& deviation).
Isolated skin laceration can be sutured.Do not
use local anesthetic containing adrenaline for
the nose.
Nasal Allergy:
Very common disease (20% of population)
Clinical picture:
recurrent attacks of sneezing, nasal itching,
watery nasal discharge.
Treatment:
Oral antihistamines
Nasal steroid therapy
Epistaxis:
F irst aid treatment is a piece of cotton soaked
with epinephrine is inserted in the nose.
Snoring:
Abnormal sound during sleep.
Sleep Apnea:
Def inition: temporary cessation of breathing
during sleep it may occur in snoring patients. It
may lead to sever medical problems
Painful & Discharging Ears
Def inition:
Earache is a common presenting symptom in
general practice. It is often a sign of ear infection
but if the ears are normal on examination you
should look for a cause of referred pain, i.e. from
the throat, teeth, sinuses, facial nerve, lymph
nodes, or wounds in the neck.
Causes:
Otitis media & perforated drum
Herpes zoster oticus
Furunculosis
Otitis externa
Chlesteatoma
Management:
1. In Otitis media, start antibiotics to avoid
complications. Give paracetamol or NSAIDs
for analgesia. Refer to ENT specialist, if
recurrent attacks or if acute perforation does
not heal in 1 month.
2. Herpes zoster if detected just after the rash
appearance, give antiviral drug as acyclovir.
3. In Furunculosis start topical antibiotics,
analgesics. It is important to exclude
diabetes.
4. Otitis externa, treat mild cases with
removal of the infected material by gentle
syringing & give topical antibiotic ear drops
e.g. gentamycin 0.3%, steroid ear drops
e.g.gentisone HC. Analgesics are needed.
Refer cases that need aural toilet to ENT
specialist.
Foreign Bodies in The Ear
Common in children.
Remove under vision with forceps, if the
V
o
l
u
m
e

4
39
Diseases & ENT
child is cooperative. Be careful not to push the
object deeper to avoid injury of the canal.
Insects can be drowned in oil & syringed
out.
Refer to ENT when extraction under general
anesthesia is considered.
Deafness
Temporary or permanent
Adult deafness
Common
2 types:
o Conductive&
Sensoneural
deafness
o Refer to ENT
Childhood deafness
Temporary is ommon
Noticed by parents or
teachers
Makes problems in
speech & behaviors
Refer to ENT
Tinnitus
Ringing or buzzing heard in the ears or head.
Occasional tinnitus is common 15%but
2% are severely affected to extent that
interferes with daily life & sleep, could lead
to depression.
Causes:
Often unknown
May accompany:
Hear loss
Noise exposure
Head injury
Menieres disease
Anemia
Hypertension
Drugs:(Loop diuretics, amino glycosides, aspirin,
NSAIDs)
Management:
Reassurance
Refer to audiologist for hearing aid if there is
deafness.
Refer to psychologist to treat associated
depression.
Refer to ENT to exclude serious causes.
Vertigo:
Def inition: An illusion that the surroundings
are spinning.
Causes:
Episodic (seconds or minutes);positional
Episodic (minutes to hours);Menieres
Prolonged(more than 24 hours)
o Peripheral lesion e.g. viral labrynthitis or
trauma
o Central lesion e.g. multiple sclerosis, tumors,
stroke.
Management:
Symptomatic treatment
Give Cinnarzine
Respiratory Tract Infection
Common Cold
Inammation of all or part of the mucosal
membranes from the nasal mucosa to the bronchi
Clinical Presentation
Multiple cases occur in family, work and school
settings.
Characterized by one or more of the following
symptoms:
1. General malaise with low grade or no
fever.
2. Nasal discharge, obstruction or
congestion.
3. Sneezing/coughing, sore throat and
hoarseness
4. Conjunctivae may be watery and
inamed.
Usually self-limited; lasting approximately 5-7
days,
Treatment
1. Oral decongestants;
2. For fever orally suggest acetaminophen,
ibuprofen, adults can use aspirin as well.
3. Warm saline gargle
4. Cough suppressants
5. Antibiotics: only if secondary bacterial
infection occurs.
B. Patient Education
Advise rest and increased oral uid intake.
Influenza
Acute viral disease of the respiratory tract
Clinical Presentation
Inuenza can occur in epidemics which last
approximately 5-6 weeks.
Characterized by abrupt onset of fever,
malaise, myalgia, headache, clear nasal
discharge, sore throat, and non-productive
cough.
Cough is usually the most frequent and
troublesome symptom and may be associated
with substernal discomfort
In individuals is history of contact to birds or
poultry, R/O Avian Flu
40
Diseases & ENT
V
o
l
u
m
e

4
Treatment
Symptomatic treatment is needed
Patient Education
Recommend rest and increased uids
Encourage cessation of smoking in
household
Teach patient to return to clinic if chest pain,
dyspnea, hemoptysis, wheezing, increased
temperature, confusion or other central
nervous system problems occur
Acute Bronchitis
Acute bronchitis involves inammation of
the bronchi that causes acute onset of cough and
sputum production.
Treatment is symptomatic and directed most
often at controlling cough:
Antitussives
Antibiotics
Corticosteroids (may be used)
Pneumonia
Acute inammation in the lung alveoli usually
secondary to infection
Signs and Symptoms
Often presents with abrupt onset of high fever,
shaking chills, productive cough of purulent
or rusty sputum, headache, prostration, and
pleuritic chest pain
Physical Examination
Assess vital signs
Observe for respiratory disease such as
cyanosis, tachypnea, intercostal retractions,
accessory muscle use, nasal aring, and
grunting
Auscultate lungs; typical ndings are the
following:
a. Localised diminished breath sounds
b. Rales and tubular breath sounds
c. Egophony (changes Patient's oe to
what sounds like ay)
d. Bronchophony (voice sounds are louder
and clearer than usual)
e. Whispered pectoriloquy (whispered
sounds are louder and clearer than
normal)
Palpate chest for tactile fremitus (palpate for
increased areas of vibration as patient says
ninety-nine or four-four in Arabic)
Percuss chest for dullness which is typical
over consolidated lung tissue
Diagnostic Tests
Plain Chest x-ray: P-A and Lateral views
Gram stain and culture of expectorated sputum
(both tests lack sensitivity and specicity but
are helpful in diagnosing infections caused
by Mycobacterium species, endemic fungi,
and Legionella species)
Do Not Forget
Treatment
A. Refer patient who appears toxic, has
haemoptysis, severe dyspnoea, a history
of a serious, chronic disease
B. Hospitalisation should be strongly
considered for patients with the
following risk factors, especially if there
are multiple risk factors present. (See
chart that follows.)
Outpatient Treatment Guidelines
for Pneumonia
Outpatient Pneumonia Without Co-morbidity
and <60 Years
Erythromycin 250-500mg tid or qid for 7-14
days
If patient is intolerant of erythromycin or is
a smoker (to treat H. inuenzae. prescribe
one of the following:
o Roxithromycin: 150-300mg every 12
hours for 7-14 days.
o Azithromycin: 500mg day 1, then
250mg daily for 4 days (take 1 Hour
before meals or 2 hours after meals).
In Egypt, azithromycin is given in a
dose of 500mg before breakfast for
three days.
o Doxycycline: 100mg bid x 7-14 days
should be used only if patient is
allergic or intolerant of macrolides.
V
o
l
u
m
e

4
41
Diseases & ENT
Outpatient Pneumonia With Co-morbidity
60 Years
Prescribe one of following:
Trimethoprim (80mg) Sulfamethoxazole
(400mg) 1 double strength tablet twice a
day for 7-14 days
Erythromycin 250-500 mg tid-qid for 7-14
days or other Macrolide (use macrolide
where Legionella species is a concern).
Beta-lactam/beta-lactamase inhibitor such
as Amoxicillin-Clavulanate 375-625mg
every 8 hours for 7-14 days.
Second generation Cephalosporin such as
Cefuroxime axetil 250-500mg every 12
hours for 7-14 days
Asthma in Adults:
Asthma is a syndrome of reversible airway obstruction, allergic inammation, and airway
Hyperresponsiveness.
Table.5: Stepwise Approach for Managing Asthma In Adults and Children Older than 5 Years of Age
Assessment Classif ication Treatment
LOOK:
Episodic shortness of breath
Wheezing
Chest tightness
Intercostal retractions
Tachypnea with prolonged expiratory phase
Cyanosis
Diaphoresis
Nasal aring
ASK:
Symptoms have seasonal, continuous,
episodic, or circadian (i.e., nocturnal
symptoms) pattern?
Conditions known to be related to asthma:
dyspnoea, dry cough, wheezy chest,
rhinitis, sinusitis, nasal polyposis, atopic
dermatitis, allergies to foods and drugs,
documented pneumonia, viral bronchitis,
and gastroesophageal reux.
Family history of allergies and asthma.
Aggravating factors such as environmental
exposure (allergens, household pets, mold,
pollen, chemicals, air pollutants, tobacco
smoke)
Step 1:
Mild Intermittent
Symptoms < 2 times a week
Asymptomatic and normal PEF between
exacerbations
Exacerbations brief (from a few hours to a
few days); intensity may vary.
Night symptoms < 2 times a month
FEV1 or PEF > 80% predicted and PEF
variability < 20%
Step 2
Mild Persistent
Symptoms > 2 times a week but < 1 time
a day
Exacerbations may affect activity
Night-time symptoms > 2 times a month
FEV, or PEF > 80% predicted and PEF
variability 20-30%
S
E
E
T
R
E
A
T
M
E
N
T
42
Diseases & ENT
V
o
l
u
m
e

4
Listen:
Cough (often occurs at night or during
exercise
Adventitious sounds
Prolonged expiratory phase of respiration
DIFFERENTIAL DIAGNOSIS
1. Tumours: benign or malignant
2. Chronic bronchitis
3. Pneumonia
4. Pulmonary embolism.
5. Congestive heart failure
6. Foreign body inhalation.
7. Allergic reactions presenting by
bronchospasm.
8. Laryngeal dysfunction
9. Cough secondary to drugs such as beta
blockers and/or angiotensin-converting
enzyme inhibitors
Step 3:
Moderate Persistent
Daily symptom
Daily use of inhaled short-acting Beta
2
-
agoinst
Exacerbations affect activity
Exacerbations > 2 times a week; may last
for days
Night-time symptoms > 1 time a week
FEV, or PEF > 60% but < 80% predicted
and PEF variability > 30%
T
A
B
E
L
S
DIAGNOSTIC TESTS
1. Spirometry or peak expiratory owrate
(PEFR) if avaliable, measured by peak
owmeter:
Increase of 15% in forced expiratory
volume in 1
st
second or 20% in forced
expiratory owafter bronchodilator
treatment
= ASTHMA
2. Chest x-ray P-A view or miniature mass
radiography (MMR)
To exclude other causes of wheezy chest,
and CBC if infection is suspected.
3. Allergy testing as Bronchial Challenge (in
specialized centers).
Step 4:
Severe Persistent
Continual symptoms
Limited physical activity
Frequent exacerbations
Frequent night-time symptoms
FEV, or PEF < 60% predicted and PEF
variability > 30%
B
E
L
O
W
Any attack not responding to ordinary
bronchodilator therapy (inhalers) is
considered acute severe asthma
Acute Severe Asthma
REFERRAL of patient to a specialist is
indicated in the following circumstances:
1. Patient has had a life-threatening acute
asthma exacerbation
2. Signs and symptoms are atypical or
uncertainty exists concerning the
diagnosis
3. Clinical problems such as nasal polyps
or severe rhinitis complicate the airway
disease.
4. Additional diagnostic testing such as
bronchoscopy, provocative challenge are
needed
5. Patient is not responding to the therapy
General:
. Oxygen
. I.V. Line
. Assurance of patients
.B2 Agonist by inhalation
REFER TO HOSPITAL
IMMEDIATLY
V
o
l
u
m
e

4
43
Diseases & ENT
Managing Asthma Long-Term
Table.6: Continued: Stepwise Approach for Managing Asthma In Adults and Children Older than 5 Years of Age
Stepwise Approach For Managing Asthma In Adults
And Children Older Than 5 Years Of Age
Goals of Asthma Treatment:
Prevent chronic and troublesome symptoms (e.g. coughing or breathlessness in the night, in
the early morning, or after exertion)
Maintain near normal pulmonary functions.
Maintain normal activity levels (including exercise and other physical activity)
Prevent recurrent exacerbations of asthma and minimize the need for emergency department
visits or Hospitalizations.
Provide optimal pharmacotherapy with minimal or no adverse effects
Meet patients and families expectations of and satisfaction with asthma care
Classify severity of Asthma
Clinical features before Treatment
Step 4
Severe Persistent
Symptoms:
Continual symptoms
Limited physical activity
Frequent exacerbation
Night-time
Symptoms:
Frequent
Step 3
Moderate Persistent
Daily symptoms
Daily use of inhaled
short-acting beta-agonist
Exacerbations affect
activity
Exacerbations 2 times
a week may last days
>1 time a week
Step 2
Mild Persistent
Symptoms > 2 times a
week but < 1 time a day
Exacerbations may affect
activity
>2 times a month
Step 1
Mild Intermittent
Symptoms 2 times a
week
A symptomatic and
normal PEF between
exacerbations
Exacerbations brief (from
a few hours to a few days)
intensity may vary
2 times a month
The presence of one of the features of severity is sufcient to place a patient in that category.
An individual should be assigned to the most severe grade in which any feature occurs. The
characteristics noted in this gure are general and may overlap because asthma is highly
variable. Furthermore, an individuals classication may change over time.
Patients at any level of severity can have mild, moderate or severe exacerbations Some
patients with intermittent asthma experience severe and life-threatening exacerbations
separated by long periods of normal lung function and no symptoms.
44
Diseases & ENT
V
o
l
u
m
e

4
Managing Asthma Long Term
Table.7: Usual Dosage for Long Term Control medications in Asthma
And Children Older Than 5 Years Of Age:
TREATMENT
STEP 4:
Severe
Persistent
STEP 3
Moderate
persistent
Long-term control
Refer then follow up for
Daily medications:
Refer then follow up for
Daily medications
Quick Relief:
Short-acting
bronchodilator:
Inhaled beta
2
-agonists as
needed for symptoms.
Short-acting
bronchodilator inhaled
beta
2
-agonists as needed
for symptoms.
Education:
Refer to group
education if available
STEP2
Mild
Persistent
One daily medication
Anti-inammatory:
either inhaled
corticosteroid (low-
dose) or cromolyn or
nedocromil (children
usually begin with a
trial of cromolyn or
nedocromil).
Sustained-release
theophyiline to serum
concentration of
5-15mcg/ml is an
alterative, but not
preferred, therapy.
Short- acting
bronchodilator: inhaled
beta
2
-agonists as needed
for symptoms.
Intensity of treatment
will depend on severity
of exacerbation.
Use of short-acting
inhaled beta
2
-agonists
on a daily basis, or
increasing use, indicates
the need for additional
long-term control
therapy.
Refer to group
education if
available
Step1 Mild
Intermittent
No daily medication
needed
Short-acting
bronchodilator:
Inhaled beta
2
-Agonists
as needed for symptoms.
Intensity of treatment
will depend on severity
of exacerbation.
Use of short-acting
inhaled beta
2
agonists
more than 2 times a
week may indicate the
need to initiate long-
term control therapy
Teach basic facts
about asthma
Teach inhaler/
spacer holding
chamber technique
Discuss roles of
medications
Develop self-
management plan
Develop action
plan for when and
how to take rescue
actions, especially
for patients with a
history of severe
exacerbations
Discuss appropriate
environmental
control measures
to avoid exposure
to known allergens
and instants.
Step down
Review treatment every 1 to 6
months.
Gradual stepwise reduction in
treatment may be possible.
Step up
If control is not maintained consider
step up. F irst, review patient medication
technique, adherence, and environmental
control of (e.g. Avoidance allergens)
V
o
l
u
m
e

4
45
Diseases & ENT
And Children Older Than 5 Years Of Age:
NOTE:
The stepwise approach presents general guidelines to assist clinical decision-making, it is not
intended to be a specic prescription, Asthma is highly variable, clinicians should tailor specic
medication plans to the needs and circumstances of individual patients.
Gain control as quickly as possible, then decrease treatment to the least medication necessary to
maintain control, Gaining control may be accomplished by either starting treatment at the step
most appropriate to the initial severity of the condition or starting at a higher level of therapy
(e.g. a course of systemic corticosteroids, higher dose of inhaled corticosteroids)
A rescue course of systemic corticosteroids may be needed at any time and at any step.
Some patients with intermittent asthma experience severe and life-threatening exacerbations
separated by long periods of normal lung function and no symptoms. This may be especially
common with exacerbations provoked by respiratory infections, a short course of systemic
corticosteroids is recommended
At each step, patients should control their environment to solve or control factors that make
their asthma worse (e.g. allergens, irritants).
Referral to an asthma specialist for consultation or co management is recommended if there are
difculties achieving or maintaining control of asthma.
Table. 8: Continued:Usual Dosage for Long-Term-Control medications in Asthma
Usual Dosages For Long - Term-control Medications
Medication:
Inhaled corticosteroids:
Beclomethasone
dipropionate

Budesonide.
Fluticasone

Triamcinolone
Acetonide
Dosage Form
50 mcg/puff
200 mcg
50 mcg,125 mcg
100 mcg/puff
Adult Dose
low dose: 200-400 mcg
medium: 400-800 mcg
high: 800-1600 mcg
low: 200-400 mcg
medium:400-600 mcg
high:>600 mcg
low: 500 mcg
medium:500-1000mcg
high: >1000mcg
low: 400-1000
medium:1000-2000mcg
high:>2000mcg
Child Dose
low: 84-336 mcg
medium: 336-672
high: >672
low: 100-200 mcg
medium:200-400 mcg
high: >400 mcg
low: 200mcg
medium: 400mcg
high: >400mcg
low:400-800mcg
medium:800-1200mcg
high: >1200mcg
Systemic Corticosteroids (Applies To All Three Systemic Corticosteroids)
Methylprednisolone
Prednisolone
Prednisone
2, 4, 8, 16, 32mg
tablets
5mg tablets
5mg/5cc, 15mg/5cc
1,2.5,5,10,20,25mg
tablets 5mg/
cc,5mg/5cc
7.5-60mg daily in a
single dose or qod as
needed for control
Short-course burst
40-60mg per day as
single or 2 divided
doses for 3-10 days
025-2mg/kg daily in
single dose or qod as
needed for control
Short course burst:
1-2mg/kg/day,
Maximum 60mg/day,
for 3-10 days
For long-term treatment of severe
persistent asthma, administer
single dose in a m. either daily or
on alternate days (alternate -day
therapy may produce less adrenal
suppression) If daily doses are
required one study suggests improved
efcacy and no increase in adrenal
suppression when administered at
3.00 p.m. (Beam et at. 1992)
Short courses or bursts are effective
for establishing control when
initiating therapy or during a period
of gradual, deterioration
The burst should be continued until
patient achieves 80% PEF personal
best or symptoms resolve. This
usually requires 3-10 days but may
require longer. There is no evidence
that tapering the dose following
improvement prevents relapse.
46
Diseases & ENT
V
o
l
u
m
e

4
Usual Dosages For Long - Term-control Medications
Cromolyn And Nedocromil:
Cromolyn
Nedocromil
MDI 1mg/puff
Nebulizer
Solution 20mg/
ampoule
MDI 1.75mg/puff
2-4 puffs tid-qid
2-4 puffs bid- qid
1-2 id-qid
1 ampule tid- qid
1-2 puffs bid-qid
One dose prior to exercise or
allergen exposure provides effective
prophylaxis for 1-2 hours
One dose prior to exercise or
allergen exposure provides effective
prophylaxis for 1-2 hours
Long- Acting Beta
2
-Agonists:
Salmeterol
Formetrol fumarate
Inhaled MDI 21
mcg/puff.
DPI 50 mcg/
blister
12 mcg/cap
2 puffs q 12 hours.
1 blister/12 hours.
1 capsule q 12 hours for
inhalation
1-2 puffs q 12 hours.
1 blister/ 12 hours.
1 cap q 12 hours
May use one dose nightly for
symptoms.
Should not be used for symptom
relief or for exacerbations.
MethyLxanthines:
Theophyline Liquids,
Sustained-
Release tablets
And capsules
Starting dose 10mg/kg/
day up to 300mg max,
usual max 800mg/day
Starting dose 10mg/
kg/day
usual max:
< 1 year of age: 0.2
(age in weeks) +5
=mg/kg/day
>1 year of age: 16mg/
kg/day
Adjust dosage to achieve serum
concentration of 5-15 mcg/ml at
steady- state (at least 48 hours on
same dosage)
Due to wide inter patient variability
in theophyiline metabolic clearance,
routine serum theophyline level
monitoring is important.
V
o
l
u
m
e

4
47
Diseases & ENT
Table. 9: Continued: Usual Dosage for Quick Relief Medication in Asthma
Usual Dosages For Quick-relief Medications
Medication
Short-Acting inhaled Beta
2
-Agnonists
Salbutamol
Terbutaline
MDI 100 mcg/puff,
100 mcg/puff
2puffs/ 5
minutes
Prior to
exercise
1-2 puffs 5
minutes prior
to exercise
An increasing use or
lack of expected effect
indicates diminished
control of asthma
Not generally
recommended for long
term treatment. Regular
use on a daily basis
indicates the need for
additional long-term-
control therapy.
Differences in potency
exist so that all products
are essentially equipo-
tent on a per puff basis,
May double usual dose
for mild exacerbations.
Nonselective agents
(i.e, epinephrine,
isoproterenol,
metaproterenol) are
not recom-mended
due to their potential
for excessive cardiac
stimulation, especially
in high doses.
Anticholinergics
Ipratropium MDI 18 mcg/puff, 200 puffs
Nebulizer solution
0.25mg/ml (0.025%)
2-3 puffs q 6
hours
0.25mg q 6
hours
1-2 puffs q 6
hours
0.25-0.5mg q 6
hours
Evidence is lacking
for anticholinergics
producing added benet
to beta
2
- agonists in long-
term asthma therapy.
Systemic corticosteroids (Applies to all three systemic corticosteroids)
Methylprednisolone
Prednisolone
Prednisone
2,4,8,16,32mg tablets
5mg tabs, 5mg/5cc,15mg/5cc
1, 2.5, 5, 10, 20, 25mg tabs,
5mg/cc, 5mg/5cc
Short
course
burst 40-
60mg/day
as single or
2 divided
doses for
3-10 days
Short course
burst 1-2mg/kg/
day.
maximum
60mg/day,for
3-10 days
Short courses or
bursts are effective
for establishing control
when Initiating therapy
or during a period of
gradual deterioration.
The burst should
be continued until
patient achieves
80% PEF personal
best or symptoms
resolve. This usually
requires 3-10 days
but may require
longer. There is no
evidence that tapering
the dose following
improvement prevents
relapse.
48
Diseases & ENT
V
o
l
u
m
e

4
Health Education for Patient and Family:
Counsel regarding danger of over use of inhalers. Patient should be using no more than 1 canister of each
type at the same time (200 metered dose inhalations of a -agonist or an equivalent amount of a dry powder
formulation).
Discuss that patient should avoid aspirin and nonsteroidal anti-inammatory drugs as about 5-20%
of adults with asthma experience severe and even fatal exacerbations of asthma while taking these
drugs.
If patient does not have egg allergy, remind patient of need for yearly inuenza vaccine.
Develop action plan on when and how to take rescue actions, especially for patients with a history of
severe exacerbations.
Follow Up
1. For acute exacerbations requiring nebulizer and/or corticosteroids, see patient within 24 hours and
then re-evaluate in 3-5 days.
Assessment of progress in chronic asthma by GP after 2 weeks after attack and every 3 months if chronic
asthma. Ask about:
Number of nocturnal attacks per week
The length taken to clear the chest in the morning
Absence from work or school
Consumption of bronchodilator preparation
2. After exacerbation has resolved completely, schedule follow up visits every 1-3 months.
A. Asthma and Pregnancy
Asthma may worsen during pregnancy. Most drugs used to treat asthma with the exception of alpha-
adrenergic compounds, bromphineramine and epinephrine, show no risk to the foetus. Corticosteroids
should be instituted when necessary. Exacerbations should be treated aggressively and effectively to
prevent fetal hypoxia.
Management of Acute Severe Asthma:
Assessing Severity
Manifestations of severe asthma include:
a. Recent emergency room visits
b. Current oral corticosteroid use
c. Previous attacks that have required the use of oral corticosteroids, a previous episode of respiratory
failure seizures with asthma attacks have been associated with severe and potentially fatal asthma.
During Physical Examination, a Severe Attack is Suggested By
Respiratory distress at rest
Difculty in speaking in sentences
Diaphoresis, or agitation
Patients with depressed mental status require intubations
A silent chest- decreased intensity of wheezing is a reliable indicator of the severity of an attack.
A respiratory rate greater than 28 breaths per minute
A pulse greater than 110 boats per minutes
Apulsus paradoxus greater than 12mm indicates severe episode. Subcutaneous emphysema should
alert the examiner to the presence of a pneumothorax or pneumomediastinum
V
o
l
u
m
e

4
49
Diseases & ENT
Impending respiratory muscle fatigue may
cause a depressed respiratory effort, paradoxic
diaphragmatic movement, and alternating
abdominal and rib cage breathing.(abdominal
alternans)
Refer
Refer to Hospital
Transfer in ambulance with:
Supplemental oxygen
Bronchodilators
Inhaled beta
2
adrenergic agonists
Systemic corticosteroids.
(Methylprednisolone is the drug
choice for IV therapy Intravenous
methylprednisolone, 125mg, given
in the emergency room (on initial
presentation) IV state of hydrocortisone
100mg).
Follow Up
Close follow-up is required for patients discharged
from the hospital or emergency room because
baseline airway hyper activity persists for 4-6 weeks
after an asthma exacerbation. A return visit to the
physician should be scheduled within 5-7 days.
Chronic Obstructive Pulmonary
Disease; COPD
Def inition:
Chronic obstructive pulmonary disease is a
disease state characterized by airow limitation
that is not fully reversible. The airow limitation
is usually both progressive, associated with an
abnormal inammatory response of the lungs to
noxious particles or gases and associated with
systemic manifestations.
Clinicopathological Def inition
Chronic Bronchitis:
Cough productive of sputum for at least 3
months of two consecutive years excluding other
cardiopulmonary diseases.
Emphysema:
An enlargement of the terminal airspace due to
destruction of the alveolar wall without brosis.
Etiology and Risk Factors for COPD
Host factors:
Genes (e.g. Alpha 1-antitrypsin deciency)
Hyperresponsiveness
Lung growth
Exposure:
Tobacco smoke
Occupational dusts and chemicals
Infections
Socioeconomic status
Indoor and outdoor pollution
Objectives of COPD Management
Prevent disease progression
Relieve symptoms
Improve exercise tolerance
Improve health status
Prevent and treat exacerbation
Prevent and treat complications
Reduce mortality
Minimize side effects from treatment
Four Components of COPD Management:
I- Assess and monitor disease
II- Reduce risk factors
III- Manage stable COPD
a. Education
b. Pharmacologic
c. Non-pharmacologic
IV- Manage exacerbations
Assess and Monitor Disease
Diagnosis of COPD is based on a history of
exposure to risk factors and the presence of airow
limitation that is not fully reversible, with or
without the presence of symptoms.
Symptoms Typical of COPD:
History for heavy smoking for many years
Cough and sputum production for many
years
Cough often present only on walking at f irst,
later cough occurs throughout the day
Sputum usually mucoid-becomes purulent
with exacerbation of disease but not
excessive.
50
Diseases & ENT
V
o
l
u
m
e

4
Cough and sputum often worse in winter due
to infection
Insidious onset of breathlessness on exertion
with wheezing or tightness of chest.
Some develop increasingly severe
exacerbation of disease leading to chronic
respiratory failure - the blue bloater type of
COPD
Others have little or no sputum or hypoxia
at rest, but breathlessness and wheezing is
severe and emphysema is prominent-the pink
puffer type of COPD
Most patients of COPD present with a mixed
pattern.
Physical Examination:
Large barrel shaped chest.
Prominent accessory respiratory muscle in
the neck
Low, at diaphragm causing costal margin
retraction on inspiration.
Diminished breath sound, distal heart sound
Prolonged expiration with generalized
wheezing
Depressed liver, which is not enlarged.
The blue bloater type of COPD may also have:
Cyanosis at rest or mild exertion
Oedema of ankles
Crackles at lung bases
Loud second heart sound in pulmonary area
(sometimes difcult to hear)
The pink puffer type of COPD may also have:
Expiratory pursed- lip breathing
Thin body built
Tendency to lean forward over a support to
assist breathing
Differential Diagnosis of COPD:
1. Asthma
2. Congestive heart failure
3. Bronchiectasis
4. Pulmonary T.B.
Assessment of Severity:
For severity assessment, referral to a chest
specialist has to be done for spirometry.
According to spirometric results, COPD can be
divided into 4 stages:
Stage Characteristics
0: At Risk Normal spirometry
Chronic symptoms (cough, sputum
production)
I: Mild COPD FEV1 / FVC < 70%
FEV1 > 80% predicted
With or without chronic symptoms (chronic
sputum production)
II: Moderate
COPD
FEV1 / FVC < 70%
30% < FEV1 < 80% predicted
III: Severe
COPD
FEV1 / FVC < 70%
FEV1 < 30% predicted or FEV1 < 50%
predicted plus respiratory failure or clinical
signs of chronic heart failure
Chest xRay:
In mild COPD, the plain chest x-ray may be
normal. With advanced emphysema changes
include:
Large volume lungs (hyperination)
Low at diaphragm
Rapid tapering of the vascular markings
Thin heart shadow
Enlarged retro-sternal air space
Chest x-ray is valuable in excluding alternative
diagnosis and / or complications.
Diagnosis of Right Heart Failure or Cor
Pulmonale;
Elevation of the jugular venous pressure and
the presence of pitting ankle edema are often
suggestive of cor pulmonale in clinical practice.
Firm diagnosis of cor pulmonale can be made
through referral for echocardiography.
Hematocrit:
Polycythemia can develop in the presence of
arterial hypoxemia, especially in continuing
smokers. Polycythemia can be identied by
hematocrit > 55%.
Reduce Risk Factors
Reduction of total personal exposure to
tobacco smoke, occupational dust and indoor
and outdoor pollutants.
Smoking cessation is the single most
effective and cost effective intervention to
reduce the risk of developing COPD and stop
its progression.
Manage Stable COPD
1. Patient Education:
Health education can play a role in improving
V
o
l
u
m
e

4
51
Diseases & ENT
skills, ability to cope with illness, and health
status. It is effective in accomplishing certain
goals, including smoking cessation.
a) Stage 0: At risk: information and
advice about reducing risk factors
e.g. smoking cessation, reduction of
indoor pollution, and reduction of
occupational exposure.
b) Stage I and II: Mild to Moderate
COPD: above topics plus
i. Information about the nature of
COPD
ii. Instructions on how to use inhalers
and other treatments
iii. Recognition and treatment of acute
exacerbations
iv. Inuenza vaccination
c) Stage III: Severe COPD: refer to the
specialist
2. Bronchodilators:
a) Bronchodilator medications are central
to the symptomatic management of
COPD.
b) Inhaled therapy is preferred
c) The choice between Anticholinergics,
Beta
2
agonist, Theophylline or
combination therapy depends on
availability and individual response
in terms of symptom relief and side
effects.
d) Long acting inhaled bronchodilators are
more convenient.
e) Stage I: Mild COPD: short acting
bronchodilators as needed e.g.
Salbutamol inhaler
f) Stage II and III: refer to specialist to
prescribe treatment, then do the patient
follow up
Manage Exacerbations
1. Increased breathlessness, the main symptom
of an exacerbation, is accompanied by
wheezes and chest tightness, increased cough
and sputum, and fever.
2. You should ask the patient about:
Duration of worsening or new
symptoms
Number of previous episodes
Present treatment regimen
3. Inhaled bronchodilators, theophylline and
systemic, preferably oral glucocortico-
steroids are effective for the treatment of
COPD exacerbations.
4. Patients experiencing exacerbations with
clinical signs of airway infection may benet
from antibiotic treatment.
5. Signs of severity are:
Use of accessory respiratory muscles
Paradoxical chest wall movement
Worsening or new onset central
cyanosis
Development of peripheral oedema
Hemodynamic instability
Signs of right heart failure
Newly occurring arrhythmia
Reduced alertness
6. If you nd any of signs of severity, refer to
hospital immediately
Commonly Used Bronchodilators in COPDS
Algorithm for management of acute
exacerbation of COPD
Commonly used Bronchodilators in COPDS
B2 agonists
Salmeterol
Formeterol
Bambeterol
Anti
cholinergics
Tiotropiun
bromide
18 ug OD
Xanthiums100-
400 mp SR/day
52
Diseases & ENT
V
o
l
u
m
e

4
Algorithm for management of acute
exacerbation Of COPD
Initiate or increase and Bronchodilators therapy
consider antibiotics Reassess within hours
Resolution or
improvement of signs
& symptoms
Continue management
step down when possible
Review long term
management
No improvement
Add oral steroids
Re assess within hours
Worsening of signs &
symptoms
Refer To hospital
Management of COPD (According to severity)
Stage I mild COPD
-FEVI >80% pred.?
- With or without
symptoms
- Short acting
bronchodilators
Stage II A FEV>80% pred
o regular with
bronchodilators
o rehabilitation
o inhaled steroids
Stage II B
30- 50% p. oral
steroids
Stage III (sever
COPD)
FEV<30%
Hospital Referral
Mucolytics and Expectorants
May be Used in Patients with
Tenacious Secretions
Oxygen:
Low-ow oxygen 2-3 L/min is indicated to
maintain oxygen tension Pao2 in the range of 55-
60mm hg. It could be given by nasal cannula or by
continuous positive airway pressure mask (CPAP)
in severe exacerbation
Mechanical ventilation is indicated in patients
with hypercapneic respiratory failure.
Smoking Cessation
Primary Health Care Physician must:
1) Ask the patient if he is a smoker or not in
every visit
2) Know how to do brief counseling asking
about:
(a) Is his patient a smoker or not?
(b) For how long is the patient smoking?
(c) How many cigarettes a day (or shisha
hagars)?
(d) Is the patient considering quitting?
(e) Number of past quit attempts
(f) Does the patient start smoking within 30
minutes of waking?
(g) Provision of advise tailoring the message
of smoking hazards to the patients
condition and the advice to quit. This
can be achieved through the 5 As:
Ask Systematically identify all tobacco users
at every visit
Advice Strong urge all tobacco users to quit
Assess Determine willingness to make a quit
attempt
Assist Aid the patient in quitting
Arrange Schedule follow up contact
Provision of self help material
3) Refer to smoking cessation clinic (in the
governorates that has such clinics) if the
patient is willing to quit
(a) With a referral form that includes:
(i) Referring clinic
(ii) Name of referring doctor
(iii) Patient health status (diagnosis)
(iv) Reason for referral
i. Health reason
ii. Preoperative
iii. For prevention of complications
of smoking
(b) Give the advice about the hazards of
passive smoking
Lung Cancer
Bronchogenic carcinoma is responsible for
>30% of cancer deaths in males and >25% in
females.
Tobacco smoking is implicated in 85% of
cases; second-hand smoke is responsible for
approximately 20% of cases. Environmental agents
V
o
l
u
m
e

4
53
Diseases & ENT
as radon exposure,asbestos,uranium and chromium
are associated with increased risk of lung cancer.
Environmental asbestos exposure is recorded with
increasing frequency in Egypt and is responsible for
a considerable number of malignancies especially
pleural tumors (mesothelioma), and lung cancer in
a minority of cases.
A proper environmental history and smoking
history are vital to suspect cases of chest
malignancies
Early diagnosis of lung cancer is crucial for cure
and good prognosis.
Any patient with chest complaints for more
than two weeks should be subjected to chest
radiography and referred for consultation to rule
out the possibility of lung cancer.
5
Management of
GIT
V
o
l
u
m
e

4
57
Management of GIT
Management of GIT
GIT
Upper GIT Symptoms:
Anorexia
Nausea and vomiting
Indigestion
Regurgitation
Heart burn
Dysphagia
Hematemesis
Melena
Hiccups
Lower GIT Symptoms:
Diarrhea: Acute-Chronic
Steatorrhea
Constipation
Fresh rectal bleeding
Borborygmi
Meteorism
Abdominal Symptoms:
- Abdominal pain: Acute-Chronic
- Flank pain
- Generallzed Abdominal SwellIng:
Ascites
Flatulance
- Focal Abdominal Swelling.
Hepatomegaly
Splenomegaly:
Flank mass
Anorexia
Anorexia
Anorexia=loss of appetite
See algorithm of anorexia and loss of weight in
T.B. section.
Anorexia Nervosa:
Main clinical criteria are:
Body weight more than 15% below standard
weight or BMI < 17.5
Weight loss is self induced
Distortion of body image; patient regards
herself as fat
Morbid fear of fatness
Amenorrhea
Treatment:
Establish agood relationship with the patient
Provide balanced diet
Eliminate purgative and /or laxative and
vomiting
Cognitive behavioral or dynamic
psychotherapeutic lines
Then you have to exclude drug cause then you
have to refer all other cases for proper diagnosis
especially persistent cases and those with
signicant weight loss
58
Management of GIT
V
o
l
u
m
e

4
No history of drug
ingestion
History of drug
ingestion
Fever No Fever
Abdominal
pain
No abdominal
pain
Alcoholism
Digitalis intoxication
Aspirin
Nonsteroidal
Anti-inammatory drugs
Antihypertensives
etc.
Acute hepatitis
Cholecystitis
Acute appendicitis
Peritonitis
Pyelonephritis
Gastroenteritis
Streptococcal
Pharyngitis in children
Meningitis
Otitis media
Any febrile illness
Pyloric or intestinal
Obstruction
Perinephric Abscess
Acute cholecystitis
Pregnancy
Pancreatic neoplasm
Acute and chronic
pancreatitis
Gastritis
Ulcer
Acute appendicitis
Diabetic acidosis
Migraine
Concussion
Cerebaal tumor or
Other mass
Food poisoning
Pregnancy
Hypercalcemia
Uremia
Pernicious anemia
Angioneurotic edema
Malingering
No headache Headache
Menieres disease
Labyrinthitis
Constant
or nearly
constant
abdominal
pain
Intermittent
Abdominal pain
No abdominal
pain
No vertigo Vertigo
Renal colic
Biliary colic
Nausea and Vomiting
Nausea and Vomiting:
Check drugs of the patient
Vertigo: illusion of movement; It is sense of
rotation of self or of surrounding.
Menieres disease:
It is recurrent attacks of Tinnitus & Vertigo ending
in deafness
On examination, there is nystagmus
Treatment: Rest
Cinnarizine: For the control of travel sickness
Adults and the elderly, and children over the
age of 12: two tablets (15mg of cinnarizine tablets)
two hours before traveling and 1 tablet every eight
hours during the journey.
Children aged 5-12 years:
One tablet (15mg of cinnarizine tablet) two hours
before traveling and tablet every eight hours during
the journey
Figure 6: Flow Chart Diagram For Differential Diagnosis of Nausea and Vomiting
V
o
l
u
m
e

4
59
Management of GIT
Mnires disease
Adults and the elderly, and children over the
age of 12:
Two tablets(15mg of cinnarizine tablets)
three times daily
Children aged 5-12 years:
One tablet (15mg of cinnarizine tablet)
three time
Resistant cases refer to surgery
Migraine:
It is recurrent headache associated with visual and
gastrointestinal disturbance
Treatment:
Relief anxiety.
Avoid dietary factors, chocolate, cheese.
Avoid contraceptive pills.
During the attack:
With aura, with onset of headache, ergotamine.
Analgesics: Paracetamol:
Adults and children 12 years: Two tablets
every 6 hours. No more than a total of 8 tablets
in any 24 hour
Antiemetic: Metoclopramide: 10mg IV or
orally 20 to 30 minutes before or with a simple
analgesic, NSAID, or ergotamine derivative
Serotonin agonists.
In between attacks:
Propranolol 10mg tds (up to 40-80mg tds)
beta-adrenergic blocker Useful for migraineurs
with concomitant hypertension, angina pectoris, and
thyrotoxicosis.
A long acting form of this drug (Inderal LA) has
been introduced.
Its once-daily dosage of 60, 80, 120 or 160mg
enhances patient compliance
* Should not be withdrawn abruptly in patients with
coronary heart disease as this action could exacerbate
coronary ischemia and eventually produce unstable
angina or myocardial infarction
Functional(nonulcer) dyspepsia:
It is the second most common functional GIT
disorder after irritable bowel syndrome. Patient can
present with a spectrum of symptoms including
upper abdominal pain/discomfort, fullness, early
satiety, bloating and nausea. These patients have no
structural abnormalities.
Alarm Features:
Dysphagia
Weight loss
Anorexia
Hematemesis or melena
Dyspepsia related to exertion
Anemia
Blood in stools
Treatment:
Reassurance, explanation and life style
modication.
Reduce intake of fat, coffee, alcohol and
cigarette smoking.
H. pylori eradication: omeprazole 20mg+
metronidazole 500mg + amoxicillin 1 g twice /d
for 2 wk
Antisecretory agents:1-Omeprazole: The adult
doses of omeprazole 20 to 40mg daily.
In children less than 2 years of age: The safety
and effectiveness have not been established
Breast feeding: Omeprazole is excreted in human
milk and, because of its potential serious adverse
reactions in nursing infants, a decision should be
made whether to discontinue breast feeding or to
discontinue the drug
2- Metclopramide.
Esophageal regurgitation: is reux of gastric
contents Avoid precipitating factors:
Stop alcohol, stop smoking, large meal,
fat, chocolate, and coffee.
Raise head of the bed at night
Simple antacids: Mucogel Magnesium
hydroxide 195mg, dried aluminium
hydroxide 220mg/5mL (low Na+).: Adults
and children over 12 years 1020mL 3
times daily, 20-60 minutes after meals,
and at bedtime or when required; Chidren
under 12 years not recommended
Metclopramide
Treatment of H. pylori
Esophageal Spasm:
Abnormal esophageal motility
Treatment:
1-Antispasmodics: Atropine sulphate, Tablets
(0.6 mg) 0.6-1.2mg at night.
Ampoules (0.6 mg) 0.61.2 mg
* Antimuscarinics should not be used in acute
abdomen to relieve the colics as this could mask
the underlying serious pathalogical lesion
60
Management of GIT
V
o
l
u
m
e

4
OR Atropine substityutes:Propantheline
bromide: Tablets:15 mg 3 times daily at least 1
hour before meals and 30 mg at night, Maximum
daily dose 120 mg.
2-Nitrates: Nitroglycerin Relaxes smooth muscle
all over the body, including those of the lower
esophageal sphincter and esophageal wall..
0.4mg sublingual 30 min ac 2.5-6.5mg, Slow
release tablet tid; not to exceed 9mg
3-Calcium channel blockers: Nifedipine
(Adalat): 10-30mg cap tid/qid 30 min ac; not to
exceed 120mg/d
Refer Patients With Signicant Body Weight
Loss.
Peptic Ulcer:
Chronic ulcers in stomach, duodenum or lower part
of esophagus.
Treatment:
Stop smoking
Proton pump inhibitors gastrazole 20mg
twice/day for 6 wk
Treatment of H.pylori
Patient with gastric ulcer must be re-endoscoped
at 6 wk to exclude malignant tumor
Gastritis
Inammation of gastric mucosa
Commonest cause is use of aspirin, NSAIDs &
alcohol
Treatment: Stop NSAIDs, alcohol
Prophylaxis therapy with omeprazole for all high
risk patients:
Over 65 yrs.
Those with peptic ulcer history
Acute Chronic
Foreign body
Botulism
Sodium Fluoride
Poisoning
Poliomyelitis
Hydrophobia
Abnormal
oropharyngeal exam
Normal
oropharyngeal exam
Glossitis
Cleft Palate
Stomatitis
Laryngitis etc
Intermittent Usually constant
For solids
only
For liquids and
solids
Other
neurologic
Findings
No other
neurologic ndings
Myasthenia
Gravis
Bulbar and
Pseudobulbar
Palsy
Schatzki Ring
With no
signicant
heartburn or pain
With
heartburn
Reux
Esophagitis.
History of
Syphilis
Male
Patient
Female
Patient
Aortic
aneurysm
Esophageal
carcinoma
Esophageal
web
Weight loss
Vomiting
No signicant weight
loss
Achalasia
Mediastinal
tumor
Dermatologic
signs
No dermatologic
signs
Scleroderma
Diffuse Esophageal
spasm
Dysphagia
Figure 7: Flow Chart Diagram For Differential Diagnosis of Dysphagia
V
o
l
u
m
e

4
61
Management of GIT
Corticosteroid therapy
Anticoagulant therapy
In patients with arthritis use Cox-2 inhibtors
Refer:
Patients symptoms are related to exertion.
Associated with other signicant symptoms.
Dysphagia
Difculty in swallowing
Myasthenia Gravis:
Acquired condition that is characterized by
weakness and fatigability of proximal limb, ocular
and bulbar muscles.
Treatment: Pyridostigmine:
Adults Oral: 30-120mg at intervals / day
Children over 6 years Oral:
Initially 60mg increased or decreased gradually
(usual dose 30-360mg/day)
Children below 6 years Oral:
Initially 30mg increased gradually (usual dose 30-
360mg/day)
Bulbar and Pseudo Bulbar Palsy:
Bulbar palsy: LMNL of cranial nerves that supply
the bulbar muscles.
Pseudo bulbar palsy: bilateral UMNL of cranial
nerves that supply the bulbar muscles leading to:
o Dysarthria
o Dysphagia
o Nasal regurgitation and nasal tone
Achalasia:
Achalasia is a disease characterized by aperistalsis in
the body of the esophagus and failure of relaxation of the
lower esophageal sphincter on initiation of swallowing
Treatment:
Refer for endoscopic dilatation of lower esophageal
sphincter or surgery
Scleroderma:
Diminished peristalsis due to replacement of the smooth muscle layers of brous tissues.
Refer all patients for proper diagnosis and management
Figure 8: Flow Chart Diagram For Differential Diagnosis of Heamatemesis
No history of
Drug Ingestion
History of
Drug Ingestion
Acute Gastritis
Gastric Ulcer
Corrosive Esophagitis
Abdominal pain
No Abdominal Pain
Gastric or Duodenal Ulcer
Hiatal Hernia and Esophagitis
Carcinoma of the stomach
preceded by
blood-free vomitus
Not preceded by
blood-free vomitus
Hepatomegaly or
Splenomegaly
No hepatomegaly or
splenomegaly
Mallory-Weiss
syndrome
Thrombocytopenic
Purpura
other blood dyscriasis
Cirrohosis
Hereditary Hemorrhagic
Telangiectasia
Aortic aneurysm
Pseudoxanthoma
Elasticum
Petichae
Cirrhosis
Portal Vein
Thrombosis
Bilharziasis
Hematemesis
62
Management of GIT
V
o
l
u
m
e

4
Mallory-weiss Syndrome:
Linear mucosal tear occurring at esophageal
junction and produced by a sudden increase in intra-
abdominal pressure.
Most patient stop spontaneously
Rarely, surgery for the tear will be required.
Hereditary Hemorrhagic
Telengectasia:
It is rare disorder with autosomal dominant
inheritance.Dilatation of capillaries and small
arterioles produces small red spots that blanch on
pressure in the skin and mucous membrane
Pseudoxanthoma Elasticum:
It is a rare disorder characterized by abnormalities
in collagen and elastic tissues affecting skin, eye
and blood vessels. Skin is loose, lax and wrinkled
associated with GIT bleeding.
Thrombocytopenia:
This is caused by reduced platelet production in
the bone marrow or excessive peripheral destruction
of platelets.
Refer for proper diagnosis and treatment.
Cirrhosis:
Cirrhosis results from the necrosis of liver cells
followed by brosis and nodule formation.
Cirrhosis leads to portal hypertension and opening
of portosystemic collaterals.
Prevention of recurrent variceal bleeding:
The risk of recurrence is 60-80% over a 2 year
period
Give oral propranol in a dose sufcient to reduce
resting pulse rate by 25%
Refer for endoscopic treatment & transjuglar
portosystemic stent shunts
Most Important Causes of
Hematemesis:
o Bleeding oesophageal varices
o Bleeding peptic ulcer.
o Acute gastric ulcer: NSAID ingestion.
o Cancer of UGIT.
What To Do If Active
Hematemesis:
Insert IV line: give blood or plasma if available.
if not give plasma expander or saline.
Maintain air way open.
Refer to emergency unit of nearest hospital.
Figure 9: Flow Chart Diagram For Differential Diagnosis of Melena
Melena
False True
Iron
Charcoal
Beet Root
No history
of drug ingestion
History of Drug
Ingestion
With
Hematemesis
Without
Hematemesis
Alcoholism
Aspirin
Anticoagulants
Caffeine
Reserpine
etc.
Esophageal Varices
Peptic Ulcer
Gastritis etc.
(see Hematemesis)
With Abdominal
Pain
Without Signicant
Abdominal Pain
Duodenal ulcer
Gastric Ulcer
Esophagitis
Mesenteric Embolism or
Thrombosis
Meckels
Diverticulum
Gastric malignancy
Blood Dyscrasias
Typhoid Fever
Carcinoma of the
Ampulla of Vater
Hereditary Telangiectasia
V
o
l
u
m
e

4
63
Management of GIT
Melena
Passage of black tarry stool due to UGI bleeding
Refer as in cases of hematemesis
No Fever
Fever
No Heartburn
or Regurgitation
Heartburn
and/or
Regurgitation
Pneumonia with pleurisy
Pericarditis
Subdiaphragmatic Abscess
Peritonitis
Epidemic Hiccups
Hiatal Hernia
and Reux
Esophagitis
Mediastinal Mass
No Mediastinal
Mass
Hodgkins disease
Bronchogenic Carcinoma
Esophageal Carcinoma
Uremia
Hysteria
Postoperative Hiccups
Tabes Dorsalis
Hiccups
Hiccups are due to involuntary diaphragmatic
contractions with closure of the glottis.This
is a result of a diaphragmatic irritation or a
metabolic cause.
Treatment:
Chlorpromazine 50mg three times daily or
diazepam 5mg three times daily.
Cause should be treated if possible.
Chlorpromazine: Adults: Oral: 25-50mg 3- 4
times / day
IM: 25- 50mg every 3-4 hours (if oral dose does
not work)
Diazepam: (Anxiolytic, hypnotic,
anticonvulsant, muscle relaxant.): Adult oral
2-5mg tds
Tabes Dorsalis:
Demyelination in the dorsal roots leading to:
Lightening pain
Ataxia
Charcot joints
Argyl Robertson pupils
Ptosis and optic atrophy
Refer Persistent Cases
Figure 10: Flow Chart Diagram For Differential Diagnosis of Hiccups
64
Management of GIT
V
o
l
u
m
e

4
Figure 11: Flow Chart Diagram For Differential Diagnosis of Acute Diarrhea
No Blood in Stool
Blood in Stool
Little or no Vomiting
Fever No Fever Severe Vomiting
Salmonella
Shigella
Campylobacter
Jejuni
Ulcerative Colitis
Amoebic
Dysentery
Giardiasis
Pseudomembraneous Colitis
Toxic staphylococcal
Gastroenteritis
Travelers diarrhea
Contaminated food
Viral gastroenteritis
Acute Diarrhea
Diarrhea:
Frequent passage of large amount of soft stool
Children with acute diarrhea refer to IMCI
(integrated management of childhood illness)
Please Do:
o Stool eramination
o Stool culture
Start Treatment According To Stool
Examination.
o If theres dehydration give oral uid &
electrolyte replacement
o Giardiasis & Amoebiasis: see Helminthes
section
o Salmonella: Ciprooxacin 500mg twice
daily
*Not to be given in children under 12 years
o Shigella: Amoxicillin or Co-Trimoxazole
o Co-Trimoxazole: Adults: Oral 960mg 12/
hrly, 480mg 12/hrly if treated more than 14
days, Children: Oral 6 w to 6 months: 120mg
12/hrly
6 months to 6 years:240mg 12/hrly
6 years to 12 years: 480mg 12/hrly or
Ciprooxacin
Campylobacter jejuni: Ciprooxacin500mg
twice daily
Staphylococcus aureus: (heat-stable
toxins): symptoms usually subside within 24
hours.
Clostridium: Metronidazole 500mg tds
daily
Travelers diarrhea: it is usually benign
and self-limiting can be treated by quinolone
Botulism: treatment is usually supportive
and antitoxins
If respiratory muscles are affected, refer to ICU
for mechanical ventilation
Pseudo membranous colitis (antibiotic-
associated diarrhea):
Stop antibiotics metronidazole 500mg tds
If patient is not responding refer
V
o
l
u
m
e

4
65
Management of GIT
No Blood in
Stool
Blood in
Stool
No / small amount of
Mucus
Large amount of
Mucus
No Mucus
Mucus
Irritable Bowel
Syndrome
Ulcerative Colitis
Crohns Disease
Pseudo-Membranous
Colitis
Carcinoma
Diverticulitis
Amoebiasis
Zollinger-Ellison Syndrome
No signs of systemic
disease
Signs of systemic
disease
Large-volume
diarrhea
Thyrotoxicosis
Hyperpara-thyroidism
Fibrocystic disease
Pellagra
Carcinoid syndrome
Addisons disease
Amyloidosis
Diabetes mellitus
Pernicious anemia
Persists during
fasting
Stops during
fasting
Zollinger-Ellison syndrome
Vasoactive Intestinal Polypeptide Tumor
Toxigenic bacteria
Giardiasis
Surreptitious drug ingestion
Lactase deciency
Steatorrhea
Other disaccharidase
Deciency
Chronic Diarrhea
Inflammatory Bowel Disease
Ulcerative Colitis:
Major symptoms are diarrhea with blood & mucus.
General features include: malaise, lethargy & anorexia
and apthus ulcers in the mouth
Crohns Disease:
Major symptoms are diarrhea, abdominal pain and
weight loss
Refer for proper diagnosis and treatment
Zollinger- Ellison Syndrome:
It is due to excessive gastrin secretion within
endocrine pancreas leading to hyposecretion of
gastric acid, leading to severe duodenal ulceration and
chronic diarrhea
Treatment by high dose omeprazole, if not
responding refer for surgery
Figure 12: Flow Chart Diagram For Differential Diagnosis of Chronic Diarrhea
66
Management of GIT
V
o
l
u
m
e

4
Irritable Bowel Syndrome:
Abdominal pain or discomfort associated with
alteration in bowel habits with no organic cause.
It is the commonest functional GI disease
Symptoms supporting diagnosis of IBS:
3/d or < 3/week stool frequency
Stools: lumps/hard or loose /watery stool
Passage of mucus
Bloating or abdominal distension
Management:
Explore dietary triggers
High ber diet for constipation
Antidiarrheal drugs for bowel frequency
Smooth muscle relaxant for pain
Reassurance
Psychotherapy
Antidepressant
Carcinoid Syndrome:
Neoplasm of APUD cells of the intestine leading
to bluish red ushing on face &neck, abdominal pain
and recurrent watery diarrhea.
Diverticulitis:
Diverticulosis: presence of diverticula in the colon
It occurs in 50% of patients over 50 years.They are
frequent in the sigmoid.It is related to low ber diet.
Diverticulitis implies inammation of the
diverticula
Acute diverticulitis is treated by Cephalosporin and
Metronidazole
Pellagra
It is found in people who eat only maize
It can also occur with INH therapy (B6 is needed for
synthesis of nicotinamide from tryptophan)
Generalized malabsorption
Very low protein diet for renal disease
In Carcinoid syndrome & Pheochromocytoma
Clinical Picture:
o Dermatitis: in exposed area to sun
o Diarrhea: glossitis and angular stomatitis
o Dementia, depression, apathy
o Treatment: vit B complex
Fibrocystic Disease:
There is alteration in the viscosity and tenacity of
mucus production at epithelial surfaces
o It includes: bronchopulmonary infections
o Pancreatic insufciency
o High sweat Na Cl concentration
o Delayed puberty & skeletal maturity
o Males are infertile
Treatment: Antibiotics for respiratory disease
Refer for treatment of pancreatic insufciency &
malnutrition
Amyloidosis
It is a disorder of protein metabolism in which there
is an extra cellular deposition of pathologic, insoluble
brillar protein in organs &tissues.
Types:
AL Amyloidosis:
It is associated with lymphopoliferative
disorders such as myeloma, and non-Hodgkins
lymphoma
Familial amyloidosis:
It leads to polyneuropathy, cardiomyopathy
Secondary amyloidosis:
It is related to chronic infections (TB,
bronchiectasis & osteomyelitis) and chronic
inammation (rheumatoid, IBD, Familiar
Mediterranean Fever)
Clinical picture is related to the organ involved:
o Kidneys: proteinuria & nephrotic syndrome
o Heart: heart failure
o Autonomic and sensory neuropathy
o Hepatosplenomegaly
o Macroglossia in 20%
Treatment:
Refer to treatment of underlying condition
Pernicious Anemia:
It is a condition in which there is atrophy of the
gastric mucosa with subsequent failure of intrinsic
factor production and vitamin B12 malabsorption
It is associated with other autoimmune diseases
Clinical Picture:
o Anemia
o Red glazed tongue
o Neurological: Sub acute combined
degeneration (SACD), polyneuropathy, deep
V
o
l
u
m
e

4
67
Management of GIT
Steatorrhea
Passage of large greasy, voluminous stool
difcult to be ushed from WC due to increased
air content
Refer for further evaluation.
Coeliac Disease (Gluten Sensitive
Enteropathy):
It is a condition in which there is an inammation
of the jejunal mucosa which improves when the
patient is treated with gluten-free diet
Gluten is contained in cereals; wheat, rye and
barley.
Treatment:
o Gluten-free diet
o Replace: iron, folic acid, calcium
o Pneumococcal vaccination /5 years
Blind Loop Syndrome (Bacterial
Overgrowth)
Treatment:
sensory loss, pyramidal.
Treatment:
Vit.B12 1000 IM/twice /wk for 3 wks then every 3 months for the rest of the patients life
Refer for further evaluation.
Adults Children
Without Pallor or
Anemia
With Pallor and
Anemia
Without Respiratory
symptoms
With Respiratory
symptoms
Celiac Disease Cystic Fibrosis
Without Jaundice With Jaundice
Without
signicant
systemic signs
With signicant
systemic signs
Obstructive
Jaundice
Malabsorption syndrome
Blind loop syndrome
Scleroderma
Amyloidosis
Chronic Pancreatitis
Pancreatic Carcinoma
Hemochromatosis
Steatorrhea
Figure 13: Flow Chart Diagram For Differential Diagnosis of Steatorrhea
68
Management of GIT
V
o
l
u
m
e

4
Rotating courses of antibiotics such as
Metronidazole, Tetracycline or Ciprooxacin
Hemochromatosis
Inherited disorder characterized by excess iron
deposition in various organs leading to functional
organic failure
Clinical picture:
o Bronzed skin
o Hepatomegaly
o Diabetes Mellitus
o Hypogonadism
o Heart failure and arrythmias
o Arthropathy
Screening: all 1st. degree family members must
be screened
Treatment: refer for proper diagnosis &
management
Pancreatitis:
Acute pancreatitis: inammation of a normal
pancreas and can return to normal after resolution
of episode
Chronic after resolution of continuing
inammation with irreversible structural changes
Causes of acute pancreatitis:
o Gall stones
o Alcohol
o Infections: mumps, Coxackie B
o Drugs: corticosteroid, estrogen, azathioprim
o Hyperlipidemia
o Idiopathic
Causes of chronic pancreatitis:
o Alcohol
o Cystic brosis
o Hypercalcemia
o Idiopathic
o Treatment: refer for proper diagnosis &
treatment
Constipation
Abdominal Pain or
Vomiting
No Abdominal Pain
or Vomiting
Complete Intestinal
Obstruction
Incomplete
Intestinal
Obstruction
Blood in
the Stool
No Blood in the
Stool
Drugs
Diet
Habit
Functional
Irritable Bowel Syndrome
Painless Defecation Painful Defecation
Hemorrhoids
anal Fissure
Colon Carcinoma
Diverticulitis
Figure 14: Flow Chart Diagram For Differential Diagnosis of Constipation
V
o
l
u
m
e

4
69
Management of GIT
Constipation is infrequent passage of hard
stools
Always do PR (per rectal) examination
Refer:
o Abnormal PR examination
o Presence of blood in Stools
o Signicant weight loss
o Signicant anaemia or high ESR
o Constipation with abdominal pain refer to
emergency unit
Intestinal obstruction, hemorrhoids &
anal f issure see surgery section
Fresh Rectal Bleeding
Severe
Mild
Mixed well with Stool Not mixed well with Stool
With
Diarrhea and
/ or Mucus
Without signicant diarrhea or
Mucus
Carcinoma of colon ulcerative colitis
Crohns disease
Meckels Diverticulitis
Coagulation Disorder
Ulcerative Colitis
Amoebic Dysentery
With signs of intestinal Obstruction Without signs of intestinal Obstruction
Intussusception, Mesenteric Thrombosis
or Embolism
Diverticulitis, Ischemic Colitis, Coagulation
Disorder
Painful Bowel Movement
Painless Bowel Movement
Anal Fissure
Thrombosed Hemorrhoid
Rectal Mass
Rectal Fistula, Proctitis
Polyp, Carcinoma, Hemorrhoids
Figure 15: Flow Chart Diagram For Differential Diagnosis of Fresh Rectal Bleeding
Always do PR examination
70
Management of GIT
V
o
l
u
m
e

4
E
x
t
r
a
-
a
b
d
o
m
i
n
a
l
A
b
d
o
m
i
n
a
l
A
c
e
t
o
n
e

b
r
e
a
t
h
P
r
o
d
u
c
t
i
v
e

c
o
u
g
h
S
h
o
c
k

a
n
d

s
h
o
r
t
n
e
s
s

o
f

b
r
e
a
t
h
F
a
m
i
l
y

o
r

p
e
r
s
o
n
a
l

h
i
s
t
o
r
y

o
f

e
p
i
l
e
p
s
y

o
r

m
i
g
r
a
i
n
e
B
l
a
c
k

a
n
c
e
s
t
r
y
B
l
a
c
k

w
i
d
o
w

s
p
i
d
e
r

b
i
t
e
D
i
a
b
e
t
i
c

a
c
i
d
o
s
i
s
P
n
e
u
m
o
n
i
a
*

M
y
o
c
a
r
d
i
a
l

i
n
f
a
r
c
t
i
o
n
E
p
i
l
e
p
s
y
M
i
g
r
a
i
n
e
S
i
c
k
l
e

c
e
l
l

A
n
e
m
i
a
*

P
e
r
s
i
s
t
e
n
t

p
a
i
n
F
o
c
a
l

t
e
n
d
e
r
n
e
s
s

a
n
d

r
e
b
o
u
n
d
G
e
n
e
r
a
l
i
z
e
d

w
i
t
h

r
e
b
o
u
n
d

t
e
n
d
e
r
n
e
s
s
R
i
g
h
t

u
p
p
e
r

q
u
a
d
r
a
n
t
A
c
u
t
e

c
h
o
l
e
c
y
s
t
i
t
i
s
A
p
p
e
n
d
i
c
i
t
i
s
S
a
l
p
i
n
g
i
t
i
s
E
c
t
o
p
i
c

p
r
e
g
n
a
n
c
y
D
i
v
e
r
t
i
c
u
l
i
t
i
s
R
e
g
i
o
n
a
l

i
l
e
i
t
i
s
L
o
w
e
r

q
u
a
d
r
a
n
t
U
l
t
r
a
s
o
u
n
d
M
e
s
e
n
t
e
r
i
c

T
h
r
o
m
b
o
s
i
s

o
r

e
m
b
o
l
i
s
m
B
l
o
o
d
y

s
t
o
o
l
S
e
r
u
m

a
m
y
l
a
s
e
A
c
u
t
e

p
a
n
c
r
e
a
t
i
t
i
s
S
h
o
c
k
B
o
a
r
d
-
l
i
k
e

r
i
g
i
d
i
t
y
P
e
r
f
o
r
a
t
e
d

u
l
c
e
r
P
l
a
i
n

x
-
r
a
y

o
f

a
b
d
o
m
e
n

a
n
d

u
p
r
i
g
h
t

f
o
r

f
r
e
e

a
i
r

u
n
d
e
r

d
i
a
p
h
r
a
g
m
S
o
n
a
r

o
r

p
l
a
i
n

x
-
r
a
y
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
F
r
a
n
k
H
e
m
a
t
u
r
i
a
R
i
g
h
t

u
p
p
e
r

q
u
a
d
r
a
n
t
S
l
i
g
h
t

j
a
u
n
d
i
c
e

o
r

d
a
r
k

u
r
i
n
e
C
h
o
l
e
l
i
t
h
i
a
s
i
s

o
r

c
h
o
l
e
d
o
c
h
o
l
i
t
h
i
a
s
i
s
U
l
t
r
a
s
o
u
n
d

o
f

g
a
l
l
b
l
a
d
d
e
r

H
i
d
a

s
c
a
n
F
l
a
t

p
l
a
t
e

o
f

a
b
d
o
m
e
n
I
n
t
e
s
t
i
n
a
l

o
b
s
t
r
u
c
t
i
o
n
H
y
p
e
r
a
c
t
i
v
e

b
o
w
e
l

s
o
u
n
d
s
T
y
m
p
a
n
y
I
n
t
e
r
m
i
t
e
n
t

c
o
l
i
c
k
y

p
a
i
n
E
E
G
E
k
g
S
e
r
i
a
l

c
a
r
d
i
a
c

e
n
z
y
m
e
s
S
p
u
t
u
m

s
m
e
a
r

a
n
d

c
u
l
t
u
r
e
,

c
h
e
s
t

x
-
r
a
y
A
c
u
t
e

A
b
d
o
m
i
n
a
l

P
a
i
n
F
i
g
u
r
e
:

1
6
:

F
l
o
w

C
h
a
r
t

D
i
a
g
r
a
m

F
o
r

D
i
f
f
e
r
e
n
t
i
a
l

D
i
a
g
n
o
s
i
s

o
f

A
c
u
t
e

A
b
d
o
m
i
n
a
l

P
a
i
n
V
o
l
u
m
e

4
71
Management of GIT
These will probably initially require
conservative management along with analgesics
and antispasmodic.
If colicky pain changed into constant pain
inammation supervene. This will be supported
by:
Raised temperature.
Tachycardia
And/or raised white cell count
Add broad spectrum antibiotics, IV line and
transfer to emergency unit
Back Pain Suggests:
Pancreatitis
Rupture of an aortic aneurysm
Renal tract disease
Diabetic Ketoacidosis (refer to Diabetic
section)
Myocardial infarction: refer to chest pain &
IHD section
Give sublingual nitrate tablet every 5 min for
3 tablets
Chew aspirin tablet
Refer to emergency unit
Sickle Cell Crisis:
IV uid
Oxygen
Antibiotics
Adequate analgesia
After attack give pneumococcal vaccine
Hemophilis inuenza vaccine
Other Causes of Acute Abdominal Pain:
Familial Mediterranean Fever
Porphyria
Familial hypertriglyceridemia
In medical causes of acute abdomen there is NO
rigidity or rebound tenderness.
N.B. Familial Mediterranean Fever is
characterized by recurrent attacks of
Fever
Arthritis: monoarticular
Serositis: abd.pain due to peritonitis or
pleurisy
Attacks last for up to 1 week
Refer to Conf irm Diagnosis
Appendicitis produces more gradual onset of
pain and pain may be made worse by movement.
Vomiting may accompany any acute abdominal
pain but, if persistent, it suggests an obstructive
lesion of the gut.
All other cases with rigidity and /or rebound
tenderness should be referred to surgical
emergency unit.
A Sudden Onset Of Severe Pain Suggests:
Perforation e.g.doudenal ulcer
Rupture e.g. of an aneurysm
Torsion e.g. of an ovarian cyst
Acute pancreatitis
Refer immediately to emergency unit
Colicky Pain Can Be Due to an Obstruction of
Gut
Biliary system
Urogenital system
Or uterus.
72
Management of GIT
V
o
l
u
m
e

4
Abdominal Pain Chronic Recurrent
Colicky
Flank may be
radiation to testicle
Midabdominal
Right upper
quadrant radiating
to shoulder
Persistent
Renal calculus
Parital intestinal
obstruction
Cholelithiasis
Localized Not Localized
Irritable Bowel
syndrome
Lower
Abdomen
Left
Diverticuliitis
Salpingitis
Endometriosis
Pyelonephritis
Flank
Associated with
jaundice radiating
to right scapula
History of
Alcoholism
Peptic ulcer
Chronic
pancreatitis
Cholelithiasis
Midhypogastrium
Right
Chronic cystitis
Bladder calculus
Obstruction
Pelvic Inammatory Disease
pelvic Appendix
Regional Ileitis
Salpingitis
Endometriosis
Upper Abdomen
Figure 17: Flow Chart Diagram For Differential Diagnosis of Abdominal Pain Chronic &Recurrent
V
o
l
u
m
e

4
73
Management of GIT
Peritoneal carcinomatosis
Chylous ascites
Treatment:
Bed rest
Dietary sodium restriction
Fluid restriction
Diuretics: spironolactone 100mg/day
You can add frusemide 20-40mg/day
Treatment of underlying conditions
If response is poor (< 0.7kg weight loss in 24
hours), refer for further evaluation & further
treatment.
Ascites
No dyspnea Dyspnea
Congestive heart
failure
Hepatomegaly No hepatomegaly
Cirrhosis of the liver
Constrictive pericarditis
Budd- chiari syndrome
Metastatic cancer
Cardiomyopathies
No signicant
proteinuria
Signicant
proteinuria
Tuperculous peritonitis
Meigssyndrome
Peritoneal carcinomatosis
Chylous ascites
Cirrhosis
Nephrotic syndrome
End- stage nephiritis
Ascites
Ascites is accumulation of uid in peritoneal
cavity
Ascites May Be:
Part of generalized oedema:
CHF
Liver Cirrhosis
Renal
Nutritional deciencies
Due to Local Cause:
TB peritonitis
Figure 18: Flow Chart Diagram For Differential Diagnosis of Ascites
74
Management of GIT
V
o
l
u
m
e

4
Abdominal Swelling
Focal (Upper)
Right Epigastrium Left
Tender Non Tender
Omental Hernia
Pancreatic cyst gastric carcinoma
Pyloric stenosis
Aortic aneurysm
Retroperitoneal sarcoma
Hepatomegaly
Splenomgaly
Abdominal wall
Hematoma
Pancreatic cyst
Gastric tumor
Colon tumor
Kidney tumor or
Enlargement
Fecal impaction
Liver in hepatitis and congestive
Heart Failure
Gallbladder in Cholecystitis
Subphrenic Abscess
Tumor of Colon
Abdominal Wall Hematoma
Hepatomegaly, renal tumor
Adrenal tumor
Courvoisier
Gallbladder
Hepatomegaly
Without Jaundice
With Jaundice
Without Splenomegaly
With Splenomegaly
Without Fever With Fever
With
Enlarged
Gallbladder
Without
Enlarged
Gallbladder
With
Enlarged
Gallbladder
Without Enlarged
Gallbladder
Cirrhosis
Bilharziasis
Amyloidosis
Congestive
Heart
Failure
Lymphoma
Leukemia
Moderate Massive
Gauchers disease
Kala azar
Other reticulo
Endotheliosis
Cholecystitis
and Ascending
Cholangitis
Infectious
Hepatitis
Malaria
Infectious
Mononucleosis
With Splenomegaly
Without splenomegaly
Primary or metastatic
Carcinoma
Cirrhosis
Hydatid disease
Congestive heart failure
Adhesive pericarditis
Wilsons disease
Glycogen storage disease
Hepatic vein thrombosis
Primary or metastatic carcinoma
Early cirrhosis
Toxic Hepatitis
Hepatic vein Thrombosis
Haemochromatosis
Carcinoma of the pancreas
Bile ducts or ampulla of vater
Hemolytic Anemia
Figure 20: Flow Chart Diagram For Differential Diagnosis of Hepatomegaly
Refer undiagnosed cases
Figure 19: Flow Chart Diagram For Differential Diagnosis of Abdominal Swelling Focal (Upper)
V
o
l
u
m
e

4
75
Management of GIT
Infectious Mononucleosis:
It is caused by Epstein-Barr virus.It occurs in
adolescents & young adults. It is transmitted by
droplet infection.
Clinical Picture:
o Fever, headache, malaise, sore throat
o Rash especially if receive ampicillin
o Cervical lymphadenopathy & splenomegaly
Diagnosis: CBC: atypical mononuclear cells
Refer for monospot test
Treatment: no specic treatment &recovery is
rapid
Kala Azar: visceral leishmaniasis
Wilsons disease (hepatolenticular
degeneration):
It is an inborn error of copper metabolism results
in copper deposition in various organs
Clinical Features:
o Liver disease
o Extra pyramidal & dementia
o Kayser Feisher ring
o Hemolytic anemia
Treatment: refer for proper diagnosis &
treatment by penicillamine
Leptospirosis
It is a zoonosis caused by spirochete
Clinical Picture:
o Severe illness consists of jaundice
o Hemorrhage
o Renal impairment
Treatment: oral doxycycline or erythromycin
Refer for proper diagnosis & treatment
Brucellosis (Malta Fever)
It is zoonosis; it spreads by ingestion of raw milk
from infected cattle.
Clinical Picture:
o Insidious onset with malaise, headache,
weakness, myalgia & night sweats.
o Intermittent fever.
o Lymphadenopathy, hepatosplenomegaly.
o Arthritis.
Refer for diagnosis.
Treatment:
Doxycyclin 200mg/d & rifampicin 600-900mg /d
for 6 weeks.
Doxycycline: For treatment of Brucellosis
(Malta fever)
Adults; 200mg/d for 6 weeks
Children: - Under 8 years: Not recommended
- Over 8 years:5mg/kg divided in 2 doses on f irst
day, followed by 2,5mg/kg/day once or
- divided on two doses on subsequent days
Rifampicin: For treatment of Brucellosis
(Malta fever)
Adult Dose: 600-900mg /d for 6 weeks orally
or IV
Pediatric Dose: 5-20mg/kg/d orally or IV once
daily or divided every12h
Bacterial Endocarditis (Infective
Endocarditis, IE)
It is an infection of the endocardium.
Prophylaxis: see rheumatic fever section.
Clinical picture of IE is varied & non-specic,
so, diagnosis must be always suspected when fever
& murmur are present.
Refer for diagnosis.
Polycythemia Rubra Vera:
It is stem cell diagnosis leading to excessive
proliferation of erythroid, myeloid &
megakaryocytic progenitor cells.
o Malaria : see helminthes section.
o TB : see T.B. section.
o SLE & Felty syndrome: see Joint section.
76
Management of GIT
V
o
l
u
m
e

4
Splenomegaly
Mild to Moderate Masssive
No Hepatomegaly
Hepatomegaly
No jaundice Jaundice
Chronic Malaria
Hepatomegaly No Hepatomegaly
Pallor and/
or Jaundice
No Pallor
Or Jaundice
Alcoholic
Cirrhosis
Schistosomiasis
Gauchers Disease
Chronic Myeloid Leukemia
Kala Azar, Myeloid Metaplasia
Thalassemia Major
Hereditary
Spherocytosis
Other Hemolytic Anemias
Collagen Disease
Chronic Malaria
Splenic Aneurysm
Lymphoma
Polycythemia vera
Pernicious Anemia No Lymphadenopathy
Lymphadenopathy
Portal Vein Thrombosis Chronic Lymphatic Leukemia
Flank Mass
Bilateral
Unilateral
Polycystic Kidney
Bilateral Hydronephosis
Not usually associated with
Hypertension
Usually associated with
Hypertension
Painful Painless
Hypernephroma
Pheochromocytoma
Adrenocortical Carcinoma
Cyst
Hydronephosis with Partial
Obstruction
Tuberculosis Perinephric Abscess
Nephroptosis
Intussusception of Colon
Congenital anomalies
Lymphoma
Enlarged Spleen
Colon Carcinoma
Wilms Tumor
Figure 21: Flow Chart Diagram For Differential Diagnosis of Splenomegaly
Figure 22: Flow Chart Diagram For Differential Diagnosis of Flank Mass
V
o
l
u
m
e

4
77
Management of GIT
Polycystic Kidney
Autosomal dominant disorders usually presents
in adults.
Characterised by: multiple renal cysts
Clinical picture:
Loin Pain, Hematuria
Hypertension
Subarachnoid haemorrhage (rupture berry
aneurysm)
Hydronephrosis
It is secondary to urinary tract obstruction
Refer
Wilmss Tumour:
It is seen in the f irst 3 years of life & may be
bilateral
Refer
Hypernephroma (Renal Cell Carcinoma)
It is the most common renal tumour in adult
Pheochromocytoma
- It is tumour of sympathetic nervous system.It
leads to secondary hypertension
Refer
Flank Pain
Pyleonehpritis: see in UT infection
6
Skin Infection &
Allergy
V
o
l
u
m
e

4
81
Skin Infection & Allergy
Dermatology
Skin reects the health condition of the body.
1. Most systemic diseases cause skin changes.
2. Some drugs produce skin changes (drug
eruption).Withdrawal of the drug usually
results in clearance of the eruption within
two weeks.
Elementary Lesions of the Skin
1. Macule:
It is a well dened area of discoloration of the
skin neither elevated above nor depressed
below the level of the skin. e.g., Freckles.
Macule is seen but not felt.
2. Papule:
palpable elevation of the skin varying in size
from 1-5mm in diameter.
3. Nodule: similar to papule but deep seated.
Its size is larger than papule. It involves both
the epidermis & dermis.
4. Vesicle:
The same size as the papule but contains
uid.
5. Bulla:
It is a cavity f illed with tissue uids. It is
larger than a vesicle.
6. Pustule:
Vesicle containing pus.
7. Wheal:
Edema of the corium. It is the elementary
lesion or Urticaria.
8. Scale:
Imperfectly keratinized horny cells adherent
together e.g. dandruf.
9. Burrow:
`Channel in the horny layer, burrowed by the
sarcoptes scabei.
10. Plaque:
area of abnormal skin or mucus membrane,
at, elevated or depressed below the level of
the skin. It is formed by coalescence of either
papules or nodules.
11. Crust:
Dried uid; blood, serumor pus.
12. Scar:
healing of injured skin by connective tissue.
13. Fissure:
Crack in epidermis.
14. Ulcer:
Crack in epidermis & dermis.
15. Erosion
Loss of epithelium down to the basal cell
layer.
Bacterial Skin Infection
1. Staphylococcus infection
20% of people are carriers; in nose, axilla &
perineum
Treatment Description Disease
Avoid spread to
other children (no
sharing of towels
&clothes)
Some schools
prohibit
attendance
until lesions are
cleared.
Treatment:
o Topical
application
of antiseptic
lotions,
o local topical
antibiotics;
Fucidin cream
o Give oral
antibiotic for
widespread
cases;
Erythromycin
or amoxicillin.
Thin walled
vesicle, rupture
easily, to
leave a yellow
crusted lesion.
1-Impetigo
(Staph. aureus)
May occur any
where
Common on face
& scalp
Spreads rapidly
&contagious.
1. Folliculitis
Infection affecting hair follicles, presents as
pustules. Management: exclude diabetes; treat
with topical and/or systemic antibiotics.
2. Scalded skin syndrome
(Toxic epidermal necrolysis) is usually in
infants. It is characterized by shedding of sheets
of skin. It may follow impetigo. Management:
Emergency pediatric admission.
82
V
o
l
u
m
e

4
2. Streptococcal infection
It is carried in the throat and/or nose.
1. Cellulitis & erysipelas
It appears as painful, tender red area with
well dened edge. Often the area is swollen
& may blister.
Management: Oral penicillin V or
erythromycin for 7-14 days. Severe infections
need hospitalization.
2. Streptococcal Intertrigo
It is chronic dermatitis with ssuring &
crusting. It occurs in between folds of skin. It
is common in infants, and obese individuals.
Skin Lesions Caused by Specific
Bacterial Infections
1. T.B. Cutis (look at T.B.)
2. Leprosy
It is chronic disease, slowly progressive,
contagious, caused by mycobacterium leprae.The
target cell for the lepra bacillus is the Schwann cell
of the nerve sheath.
Types:
Lepromatous Leprosy
Tuberculoid Leprosy
Borderline Leprosy
Intermediate Leprosy
The full blown picture is decreasing.
Do Not Forget
When you suspect refer to specialist.
Viral Skin Lesions
1. Viral warts (Verrucae) are caused by human
papilloma virus.
The virus is transmitted by direct contact.
Certain types are associated with infection at
different sites. Genital warts are associated
with cervical dysplasia.
Treatments look at minor surgery.
2. Molluscum contagiosum:
Glistening hemispherical umbilicated
papule. Treatment as virus warts
3. Herpes simplex
It is common acute vesicular eruption.
It can affect eye, mouth, vulva, vagina etc
Gingivo stomatitis
Vulvo vaginitis
Kerato conjunctivitis
Eczema Herpiticorum
Dissiminated form
Recurrent type
Treatment:
General:
Give antibiotic to control secondary
infection.
Give analgesics for the pain.
Local:
Antiseptic solution
Topical application of I.D.U.(5-iodo-2-
dioxy-uridine) As 0.1% eye drops in corneal
lesions
4. Chicken pox (Varicella)
Look at IMCI
5. Herpes zoster
Acute vesicular eruption caused by a neurotropic
virus related to that of Varicella & is located in the
posterior root ganglia & posterior nerve roots.
Types depend upon the nerve involved & severity
of the lesion.
Treatment:
Refer to specialist, every case should be
investigated.
Fungal Infection
1. Dermatophyte Infection (Tinea)
It affects skin, nails or hairs.
Tinea corporis affects trunk or limbs
(ringworm of the body) (Tinea Circinata).
Tinea pedis affects feet (athletic foot).
Tinea cruris affect groin.
Tinea capitis affects hair & scalp.(ring worm
of the scalp)
V
o
l
u
m
e

4
83
Good rule
Assume that any bald area or scaly patch
in the scalp of a child is due to ring worm till
proved otherwise.
Tinea unguium affects nails, toenails &
ngernails.
Diagnosis is by clinical picture. Skin scraping or
nail clippings may conrmdiagnosis.
Treatment:
General: Griseofulvin in extensive types (refer
to specialist)
Local:
Whiteeld ointment
Tincture iodine 2-5%
2. Candidiasis (Candidosis) (Monilliasis)
It is uniform commensal of the mouth & gut
which produces opportunistic infection.
Risk factors
Moist
Opposing skin folds
Obesity
Diabetes mellitus
Neonates
Pregnancy
Poor hygiene
Humid environment
Wet work occupation
Use of broad spectrum antibiotics.
Presentation of Candidiasis:
Genital infection
Intertrigo (submammary, inguinal & axillary
folds)
Oral (sore mouth) (Thrush)
Nappy Candidiasis
Chronic paronychia
Systemic Candidiasis (occurs in
immunosuppressed individuals)
Management
1. Topical treatment
Nystatin or Miconazole are available in many
forms as cream, pessaries, spray, powder,
oral pastilles or gels.
2. Systemic treatment use for recurrent,
extensive, systemic or resistant infection &
nail or scalp infection. Oral uconazole 50mg
once/day for two weeks is effective foe oral,
mucocutaneous or systemic Candidiasis.
Higher doses may be needed if
immunosuppressed, seek specialist advice.
A single oral dose of 150mg uconazole is
effective for genital Candidiasis.
Terbinane (lamisil) is for Dermatophyte
infection.
3. General measures, keep body folds
separated& dry, minimize hot & humid
conditions & keep mouth & tongue clean by
brushing twice a day.
Skin Diseases Caused by Parasites
1- Pediculosis
There are two species of human lice:
a-Phthirus pubis, it affects the pubic hair
Clinical picture: continuous intense itching
in the infested area. Blood pigments & signs of
secondary infection.
Treatment
Good hygiene
Shaving of the hair
2% ammoniated mercury ointment
10% benzyle benzoate emulsion
b-Pediculosis humanus (PH)
-PH capitus i.e. it affects the scalp
-PH corporis i.e. it affects the body
Clinical picture:
Continuous itching
Secondary infection
Regional lymphadenitis
In case of scalp affection nits can be identied
cemented to hair
Treatment:
Good hygiene, health education & avoidance of
crowd
10% DDT in liquid parafn applied for one night
Repeated every 3 weeks.
84
V
o
l
u
m
e

4
2-Scabies
The scabies mite (sarcoptes scabei) is 1/2mm
long & spread by physical contact. Symptoms
appear 4-6 weeks after infection.
Treat with scabicide e.g., malathion lotion.
All close contacts need treatment.
Advise the patients to launder all worn
clothes & bedding after application.
Give oral antihistamines for symptomatic
relief.
Insect bites
Immediately after the bite, remove any sting
present in the wound; often no further treatment is
needed.
If anaphylaxis occurs, give subcutaneous
adrenaline, oxygen & refer to emergency
department of the nearest hospital.
If severe local reaction apply ice pack, give oral
antihistamine 4-6 hourly.
Health education: to remove the source of
insects.
Eczema
Allergic itchy dermatitis caused by factor
characterized by making vesicles
Types of eczema:
Contact dermatitis
Atopic dermatitis
Seborrheic dermatitis
Pompholyx
Dry (Aseatotic)(eczema craquele)
Varicose
Dandruff
Discoid (nummular)
Management
1. Refer if uncertain diagnosis or resistant to
treatment.
2. Emollients: e.g. aqueous cream, emulsifying
ointment, bath emollients use regularly on
skin & as soap substitute.
3. Topical steroids
4. Antibiotics: for infected eczema-oral or
topical.
5. Antihistamines at night to decrease desire for
itching.
Urticaria & Angioedema
It is transient itchy reaction of skin characterized
by formation of wheals.
Types:
Acute Urticaria
Chronic Urticaria
Physical Urticaria
Contact Urticaria
Drug induced Urticaria
Hereditary Angioderma
Urticaria with systemic disease
Urticaria with pregnancy
Management
Eliminate any underlying cause if possible
Avoid provoking factors
Antihistamines
Corticosteroids
Diet-dietary salicylates aggravate chronic
Urticaria, azo dyes &benzoic preservatives
produce exacerbation refer to dietician.
Pityriasis
Pityriasis rosea is an acute cutaneous eruption of
limited course & minimal symptoms.
1. The eruption develops suddenly by the appearance of the
Herald patch(a well dened rounded or oval plaque rosy red &
covered by a ne small adherent scales on its periphery
2. After few days up to two weeks the secondary eruption
appears in crops(They are oval patches, dull pink with clear
center & collarets scaly margin)
Treatment:
Antihistamines.
Calamine lotion, Topical steroid
Psoriasis
Psoriasis is a chronic non-infectious
inammatory skin condition characterized
by well demarcated erythematous plaques
topped by silvery scales.
Classication according to distribution:
Scalp psoriasis
Flexural psoriasis
Penile psoriasis
Ungual psoriasis (nail psoriasis)
Psoriasis of palm & sole (hyperkeratotic)
Psoriasis-arthropathica
V
o
l
u
m
e

4
85
Pustular psoriasis
Management:
Health education, all patients need
explanation of the condition & possible
treatment options.
Refer to dermatology
Follow up
Lichen Planus
It is inammatory, itchy dermatoses.
It is characterized by scaly erythematous
eruption.
Types:
Lichen planus annularis
Lichen planus hypertrophicus
Lichen planus linearis
Lichen planus moniliformis
Lichen planus atrophicus
Lichen planus bullosus
Lichen planus atropicus (actinicus)
Management:
It is self limiting in most cases.
Topical steroids are used
Refer to specialist
Acne Vulgaris
(seborrhoeic eruption)
Predisposing factors
Anxiety
Menstrual irregularities
Mild anemia
Hypovitaminosis A
Toxic absorption of septic foci
Constipation
Hormonal dysfunction
Types
Commedo type(black or white heads)
Papular type
Pustular type
Indurated type
Excoriated
Occupational(exposure to chlorinated
organic compounds)
Drug induced(e.g. iodide, bromide,
anticoagulants)
Cystic type
Mixed type
Conglomerate type
Keloidal acne
Atrophied acne
Treatment:
Good health
Personal hygiene
Exercise
Balanced diet, avoid excess fat
Topical:
Lotions as 2% sulphur in calamine
Sulphur soap
Ultraviolet ray
Systemic:
- Tetracycline in small repeated doses on
prolonged time
- Long acting sulpha
- Vitamin A
Autogenous vaccine (if staff infection)-
Estrogen-
Surgery: small incision to express contents-
Dermaberation for residual scars
Volume 4
86
V
o
l
u
m
e

4
Guideline Development Group Acknowledgements
1 Cairo University Consultancy group :
Professor Dr. Laila Kamel Professor of Public Health& Community Medicine
Cairo University, Faculty of Medicine
Professor Dr. Nagwa Eid Professor of Internal Medicine ,
Professor Dr. Salma Dawara Professor of General Surgery
Dr. Abeer Barakat Lecturer of Public Health
2- Sector of Technical Support and Project Technical Working
&Supervisory Group :
Dr. Emam Moussa Head of the Central Administration of the Technical
Support and Project & Group Leader
Dr. Soad Abdel Megid Guideline Developer & Groups Coordinator
Dr. Osama Abdel Azim Technical Advisor
3- Additional Support and F irst Draft Revision:
MOHP Level
All 1st Undersecretary , and Undersecretary of the MOHP Sectors and Central Administrations
are involved in revising the Document
Medical University Staff and Institutions
Professor Dr. Mahmoud Serry Professor of Chest ,
Ein Shams University
Professor Dr. Omima El Gebally Professor of Family Med ,
Assiut University
Professor Dr. Fathy Maklady Professor of Family Med & General Medicine ,
Canal El Suez University
Professor Dr. Esmat Shiba Professor of Family Med & General Medicine ,
Cairo University
Professor Dr. Hesham Zaher Professor of Dermatology ,
Cairo University
Professor Dr. Ezz El Dine Osman Professor of OB/Gyn ,
Cairo University
Professor Dr. Tarek Kamel Professor of ENT ,
Cairo University
Volume 4
V
o
l
u
m
e

4
87
Professor Dr. Magda Badawy Professor of Pediatric ,
Cairo University
Professor Dr. Tagrieed Farahatt Professor & Head Department of Family medicine ,
Monoya University
Professor Dr. Sawsan Fahmy Professor of Public Health , Alex ,
High Institute of Public Health
Professor Dr. Osman Ziko Professor of Ophthalmology ,
Ein Shams University
Professor Dr. Amr El Noury Consultant of Clinical Guideline MOHP General
Hospital
4- Revision of Pharmaceutical Sections :
Professor Dr. Hider Galeb Professor of Pharmacology ,
Cairo University
Professor Dr. Abdel Rahman El Nagar Professor of Clinical Pharmacology ,
Faculty of Medicine ,Cairo University
Professor Dr. Aza Monier Agha Professor of Pharmacology,
Faculty of Pharmacy, Cairo University
Professor Dr. Faten Abdel Fatah Professor of Clinical Lab "
Institute of Pharmaceutical Monitoring"
Dr. Mohamed Awad Lecturar of Pharmacology ,
Faculty of Pharmacy, Helwan University
Dr. Alaa Mokhtar Director of HSRP Pharmaceutical Program
Dr. Gebriel Ali MOHP, Information Center ,
Central Administration of pharmacy
Dr. Mostafa Sleim Pharmaceuticals Consultant at MOHP
5- Revision By High Committee of Egyptian Board of Family Medicine
Professor Dr. Gabr Metwally Professor of Public Health
Al Azher Unversity for boys
Professor Dr. Mohamed Farghally Professor of Public Health
Al Azher Unversity for boys
Professor Dr. Adel Fouda Professor of Public Health
Zagazig University
Volume 4
88
V
o
l
u
m
e

4
6- Family Physician Participating in the Review of the F irst Draft and Field
testing of the Document at Governorate levels:
Governorate level
Sohag
Dr. Mazhar Attia Ahmed El Shik Shebl , FHU
Dr. Gerges Khalil Krns El Gazazra FHU
Dr. Emad Latif Metiass El Shik Yosef FHU
Dr. Komyl Wdiee Danial Bahta FHU
Dr. Kadry Mohamed Attia Erabat Abu Ezize FHU
Dr. Emad Naeeim Loka Bahatyl El Gizira FHU
Dr. Hala Samuaeil Fares TST Quality Specialest
Dr. Frag Ahmed Mahmoud TST Primary Health Care Director
Governorate level
" Qena"
Dr. Nahla Shikhoon El Mkrbya FHU
Dr. Nesreen Abu El Abass Elian El Hragia FHU
Dr. Eiman Mohamed Mahfouz Gzyra Motira FHU
Dr. Mona Fakhry Ali El Hogirat FHU
Dr. Mohamed Mohamed Ashour El Homer Wal Gaafraa FHU
Dr. Mostafa Glal Osman El Tob FHU
Dr. Ahmed Saad Ahmed TST Coordinator
Dr. Mamdouh Abuel Kasem TST
Governorate level
" Monoya"
Dr. Tamer Farag Ali Mastay FHU
Dr. Alaa El Dine Abdel Razek Ashliem FHU
Dr. Sherif Mosaad Labib El Remally FHU
Dr. Asmaa Mahmoud El Sayed Shobra Bakhom FHU
Dr. Waleid Mohamed Rashad Meit Bara FHU
Dr. Nahed Sobhy Mahmoud Tymor FHU
Dr. Gehad Ibrahim Mohamed TST
Volume 4
V
o
l
u
m
e

4
89
Governorate level
" Alexandria"
Dr. Naira Niazy Alexandria Central Coordinator
Dr. Nagwa Mostafa Abuel Nazar El Gomrok FHU
Dr. Ghada Mohamed Abdel Allah El Gomrok FHU
Dr. Marian Nashaat El Manshia2
Dr. Ihab Zaky Iraheeim El Laban1 FHU
Dr. Riham Sabry El Laban1 FHU
Dr. Nadia Khaliel Fahmy El Laban2 FHU
Dr. Anas Mohamed Helal TST
Dr. Maha Mogib Haseib TST
Dr. Sanaa Ahmed Elbrsiky TST
Governorate level
"Suez"
Dr. Zein El Abedein Abdel Motelb El Safaa FHU
Dr. Saher Mahmoud Hussien El Amal FHU
Dr. Amany Keshk El Sweiz1 FHU
Dr. Mervet Gharieeb El Mothalath FHU
Dr. Suzan Gamiel 24 October FHU
Dr. Hany Anter El Mashroo FHU
Dr. Nadia Mohamed Esmaeil TST
Dr. Magda Ahmed Mohamed TST Coordinator

Practice Guidelines: For Family Physicians

Uploaded by

Copyright:

Available Formats

Practice Guidelines: For Family Physicians

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Practice Guidelines: For Family Physicians

Uploaded by

Copyright:

Available Formats

Practice Guidelines

For Family Physicians

Stop Responsible Drug!

You might also like